Shire CONFI DENTIAL Page 6
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
PRODUCT QUALITY  COMPLAINTS
Investigators are required to report investigational product quality  complaints to Shire within 
24hours. This includes any  instances wherein the quality  or performance of a Shire product 
(marketed or investigational) does not meet expecta tions (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different
products).  For instructions on reporting adverse events (AEs) related to product complaints, see 
Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference if needed):
Shire, Lexington, MA (USA)

Shire CONFI DENTIAL Page 7
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
TABLE OF  CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSI ON........................................................3
EMERGENCY CONTACT I NFORMATION ................................................................................5
PRODUCT QUALITY COMP LAINTS ..........................................................................................6
TABLE OF CONTENTS .................................................................................................................7
LIST OF TABLES .........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES ................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
DEFIN IT
IONS...............................................................................................................................14
STUDY SYNOPSI S
......................................................................................................................15
STUDY SCHEDULES ..................................................................................................................22
1.BACKGROUND INFORMATI ON.......................................................................................31
1.1 Indication and Current Tre atment Options
...............................................................31
1.2 Product Background and Clinical I nformation ........................................................31
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................32
2.1 Rationale for the Study ................................ ................................ ............................. 32
2.2 Study  Objectives ......................................................................................................33
2.2.1 Primary  Objectives .................................................................................................33
2.2.2 Secondary  Objective s
.............................................................................................33
2.2.3 Exploratory  Objectives ..........................................................................................34
3.STUDY DESIGN ...................................................................................................................34
3.1 Study  Design and Flow Chart ..................................................................................34
3.2 Duration and Study  Completion Definition .............................................................37
3.3 Sites and Regions ................................ ................................ ................................ .....37
4.STUDY POPUL ATION................................ ................................ ................................ ......... 37
4.1 Inclusion Criteria................................ ................................ ................................ ......37
4.2 Exclusion Criteria ................................ ................................ ................................ .....38
4.3 Re-randomization ................................ ................................ ................................ .....40
4.4 R eproductive Potential .............................................................................................40
4.4.1 Female Contraception ................................ ................................ ............................ 40
4.5 Discontinuation of Subjects ................................ ................................ ..................... 41
4.5.1 Reasons fo r Discontinuation ................................ ................................ .................. 41
4.5.2 Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................................42
5.PRIOR AND CONCOMITAN T TREATMENT ...................................................................42
Shire CONFI DENTIAL Page 8
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
5.1 Prior Treatment ........................................................................................................42
5.2 Concomitant Treatment ............................................................................................42
5.3 Prohibited Treatment ................................................................................................43
6.INVESTIGAT IONAL PRODUC T
........................................................................................44
6.1 Identity  of Investigational Product ...........................................................................44
6.1.1 Blinding the Treatment Assignment ......................................................................44
6.2 Administration of I nvestigational Product(s) ...........................................................44
6.2.1 Interactive Response Technology  for Investigational Product Management ........44
6.2.2 Allocation of Subjects to Treatment ......................................................................44
6.2.3 Dosing ....................................................................................................................45
6.2.4 Unblinding the Treatment Assignment ..................................................................46
6.3 Labeling, Packa ging, Storage, and Handling
...........................................................46
6.3.1 Labeling .................................................................................................................46
6.3.2 Packaging ...............................................................................................................47
6.3.3 Storage ...................................................................................................................47
6.4 Drug Accountability .................................................................................................48
6.5 Subject Compliance ..................................................................................................49
7.
STUDY PROCEDURES........................................................................................................49
7.1 Study  Schedule ................................ ................................ ................................ ......... 49
7.1.1 Screening Period ....................................................................................................49
7.1.1.1
Screening Visit (Visit 1).........................................................................49
7.1.1.2 Recommended Te lephone Call (Day  ⎼7 to ⎼4)......................................52
7.1.1.3 Baseline Visit (Visit 2) ...........................................................................52
7.1.1.4 Subject Visit Schedule Summary  Post -baseline .....................................54
7.1.2
Double- blind Acute Phase .....................................................................................54
7.1.2.1 Recommended Telephone Call (Day ⎼7 to ⎼4)......................................54
7.1.2.2
Double- blind Acute Phase Weeks 2 and 4 (Visi ts 3 and 3.1, 
respectivel y)...........................................................................................54
7.1.2.3
Double- blind Acute Phase Week 8/Withdrawal (Visit 3.2) ...................55
7.1.3 Open -
label Acute Phase................................ ................................ ......................... 56
7.1.3.1 Recommended Telephone Call (Day s ⎼7 to ⎼4)................................ ....56
7.1.3.2 Open -label Acute Phase Weeks 2 and 4 (Visits 4 and 4.1, 
respectivel y)................................ ................................ ........................... 56
7.1.3.3 Open -label Acute Phase Week 8/Withdrawal (Visit 4.2) .......................56
7.1.4
Double-blind Maintenance Phase ................................ ................................ .......... 57
7.1.4.1 Recommended Telephone Call (Day s ⎼7 to ⎼4)................................ ....57
7.1.4.2 Double-blind Maintenance Phase Weeks 2 -4 (Visit 5) .......................... 57
7.1.4.3 Double- blind Maintenance Phase Week 13 (Visit 5.1) ..........................58
Shire CONFI DENTIAL Page 9
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
7.1.4.4 Double-blind Maintenance Phase Wee k 26/Withdrawal (Visit 5.2) ......58
7.1.5 Follow -up Period (Visit 6) .....................................................................................59
7.1.6
Additional Care of Subjects After the Study .........................................................59
7.2 Study  Evaluations and Procedures
...........................................................................59
7.2.1 Efficacy ..................................................................................................................59
7.2.1.1 Partial UC -
DAI Score ............................................................................60
7.2.1.2 Modified Full UC - DAI Score ................................ ................................ 62
7.2.2 Safety .....................................................................................................................63
7.2.2.1 Medical and Medication History ............................................................64
7.2.2.2 Physical Examination .............................................................................64
7.2.2.3 Height and Weight .................................................................................64
7.2.2.4
Adverse Event Collection.......................................................................64
7.2.2.5 Vital Signs ..............................................................................................64
7.2.2.6 Clinical L aboratory  Evaluations .............................................................65
7.2.2.7 Pregnancy  Test .......................................................................................66
7.2.2.8 Stool Assessment ....................................................................................66
7.2.3 Pharmacokinetic Procedures ..................................................................................67
7.2.3.1
Blood Sample Collection and Handling Procedures ..............................67
7.2.3.2 Shipment o f Plasma Pharmacokinetic Samples .....................................68
7.2.3.3 Plasma Drug Assay  Methodology ..........................................................68
............................................................................68
7.2.4.1 Health
-related Quality -of-Life Assessments..........................................69
7.2.5 Volume of Blood to be Drawn from Each Subject ................................................71
8.ADVERSE AND SERIOUS ADVERSE EVENTS A SSESSMENT ....................................71
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................71
8.1.1 Severity  Categorization ..........................................................................................72
8.1.2 Relationship Categorization ...................................................................................72
8.1.3 Outcome Categorization ................................ ................................ ........................ 73
8.1.4 Symptoms of the Disease Under Study ................................ ................................ .73
8.1.5 Clinical L aboratory  and Other Safet y Evaluations ................................................73
8.1.6 Pregnancy ................................ ................................ ................................ ............... 74
8.1.7 Abuse, Misuse, Overdose, and Medicati on Error ................................ .................. 74
8.2 Serious Adverse Event Procedures ................................ ................................ .......... 75
8.2.1 Reference Safet y Information ................................ ................................ ................ 75
8.2.2 Reporting Procedures ................................ ................................ ............................. 75
8.2.3 Serious Adverse Event Definition ................................ ................................ ......... 76
8.2.4 Serious Adverse Event Collection Timeframe ................................ ...................... 76

Shire CONFI DENTIAL Page 10
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................76
8.2.6 Fatal Outcome ........................................................................................................77
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, an d Site 
Reporting................................................................................................................77
9.DATA MANAGEMENT AND STATISTICAL METHODS
...............................................77
9.1 Data Collection .........................................................................................................77
9.2
Clinical Data Management .......................................................................................77
9.3
Data Handling Considerations..................................................................................78
9.4 Statistical Analy
sis Process ......................................................................................78
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......78
9.6
Sample Size Calculation and Power Considerations................................................79
9.7 Study  Population ......................................................................................................79
9.8 Efficacy  Anal yses.....................................................................................................79
9.8.1 Primary  Efficacy  Endpoint ....................................................................................79
9.8.1.1
Double- blind Acute Phase ......................................................................79
9.8.1.2
Double-blind Maintenance Phase...........................................................80
9.8.2 Sensitivity  Anal yses of the Primary  Endpoint .......................................................80
9.8.3 Secondary  Efficacy  Endpoints ...............................................................................80
9.8.3.1
Double- blind Acute Phase ......................................................................81
9.8.3.2
Double-blind Maintenance Phase...........................................................81
9.8.4 Exploratory  Efficac y Endpoints .............................................................................81
9.8.5 Exploratory  Pharmacokinetic Endpoint
.................................................................82
9.9 Safety  Anal yses........................................................................................................82
9.10 Other Anal yses.........................................................................................................83
9.10.1 Health
-related Quality -of-Life Anal yses...............................................................83
10.SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................83
10.1 Sponsor’s Responsibilities .......................................................................................83
10.1.1 Good Clinical Practice Compliance ................................ ................................ .......83
10.1.2 Indemnity /Liability  and Insurance ................................ ................................ ......... 83
10.1.3 Public Posting of Study  Information ................................ ................................ ......84
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................84
10.1.5 Study  Suspension, Termination, and Completion
..................................................84
10.2 Investigator’s Responsibilities .................................................................................84
10.2.1 Good Clinical Pra ctice Compliance ................................ ................................ .......84
10.2.2 Protocol Adherence and Investigator Agreement ................................ .................. 85
10.2.3 Documentation and Retention of Records ................................ ............................. 85
10.2.3.1 Electronic Case Report Forms................................ ................................ 85
Shire CONFI DENTIAL Page 11
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................85
10.2.3.3 Audit/I nspection .....................................................................................86
10.2.3.4 Financial Disclosure ...............................................................................86
10.3 Ethical Considerations ..............................................................................................86
10.3.1 Informed Consent/Assen t
.......................................................................................86
10.3.2 Institutional Review Board or Ethics Committee ..................................................87
10.4 Privacy  and Confidentiality ......................................................................................88
10.5 Study Results/Publication Policy .............................................................................88
11.REFERENCES .......................................................................................................................90
12.APPENDI CES ........................................................................................................................91
Shire CONFI DENTIAL Page 12
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
LIST  OF TABLES
Table 1: Double- blind Acute Phase .............................................................................22
Table 2: Open -
label Acute Phase ................................................................................26
Table 3: Double
-blind Maintenance Phase..................................................................28
Table 4: Minimally  Required Number of Subjects per Weight Group
.......................35
Table 5: Common Prior Excluded Treatments ............................................................43
Table 6: Volume of Blood to be Drawn From Each Subject
.......................................71
LIST  OF FIGURES
Figure 1 : Study  Design Flow Chart ..............................................................................36
LIST  OF APPENDICES
Appendix 1
Protocol History.............................................................................................92
Appendix 2 The Modified Full Ulcerative Colitis Disease Activity  Index 
(UC-DAI) ....................................................................................................100
Appendix 3 Subject Questionnaires ................................................................................101
Appendix 4 Pediatric Ulcerative Colitis Activity  Index .................................................102
.......................................................................103

Shire CONFI DENTIAL Page 13
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
ABBREVIA TIONS
5-ASA 5-aminosalicy lic acid
Ac-5-ASA acetyl-5-aminosalicy lic acid
AE adverse event
CMH Cochran -Mantel -Haenszel
CRO contract research organization
DMC Data Monitoring Committee
DUCS Daily  Ulcerative Colitis Scale
EC Ethics Committee
eCRF electronic case report form
e-diary electronic dia ry
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
-HCG beta-human chorionic gonadotropin
ICH International Council for Harmonisation
IRB Institutional Review Board
IRT interactive response technology
LAR legally  auth orized representative
MMXMulti -Matrix Sy stem
PGA Physician’s Global Assessment
PRO patient -reported outcome
PUCAI Pediatric Ulcerative Colitis Activity  Index
ObsRO observer -reported outcome
SAE serious adverse event
SAP statistical analy sis plan
TEAE treatment -emergent adverse event
UC ulcerative colitis
UC-DAI Ulcerative Colitis Disease Activity  Index
US United States
Shire CONFI DENTIAL Page 14
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
DEFINITIONS
Clinical response: partial Ulcerative Colitis Disease Activity  Index ( UC-DAI)≤1 (with rectal 
bleeding=0 andstool frequency  ≤1 andPhysician’s Global Assessment [ PGA ]=0)
Clinical and endoscopic response: UC-DAI ≤2 (with rectal bleeding=0 andstool frequency ≤1
andPGA=0 )andwith mucosal healing (endoscopy  score ≤1) based on centr al reading
Shire CONFI DENTIAL Page 15
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
STUDY  SYNOPSIS
Protocol num ber:  SPD476 -319 Drug: MMX Mesalamine/mesalazine
Title of the study:  A Phase 3, Multicenter, Randomized, Double -blind Study to Determine the Safety and 
Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects wit h Mild to Moderate Ulcerative Colitis, in 
both Acute and Maintenance Phases
Number of subjects (total and for each treatm ent arm):
More than 100 subjects w ill be screened, and up to 80subjects will be enrolled in the Double -blind Acute Phase 
of the study . More than 65 subjects w ill be screened (in addition to an expected 28 subjects who will enter the 
Double -blind Maintenance Phase from one of the Acute Phases) and a t least 80subjects will be enrolled in the 
Double -blind Maintenance Phase of the study.
Investigators: Multicenter study
Sites and Regions: 
It is anticipated that sites in the following regions will participate: North America, Europe, and the Middle East.  
Approximately 48 active study sites are planned.
Study period (planned):
2013 -2018Clinical phase: 3
Objectives:
Prim ary:  
The primary objective of the Double -blind Acute Phase of the study is to assess clinical response to 
Multi -Matrix System ( MMX®)mesalamine/mesalazine between a low  and high dose in children and 
adolescents aged 5 -17years with mild to moderate ulcerative colitis ( UC).
The primary objective of the Double -blind Maintenance Phase of the study is to assess maintenance of clinical 
response to MMX mesalamine/mesalazine between a low  and high dose in children and adolescent s aged 
5-17years who are in remission.
Secondary:
Double -blind Acute Phase  
The secondary objectives of the Double -blind Acute Phase are to :
 Assess clinical and endoscopic response to treatment with MMX mesalamine/mesalazine betw een a low 
and high dose i n children and adolescents aged 5 -17 years with mild to moderate UC in the Double -blind 
Acute Phase
 Assess changes in the Daily Ulcerative Colitis Scale (DUCS) for children and caregivers betw een a low  
and high dose of MMX mesalamine/mesalazine in children and adolescents aged 5 -17 years w ith mild to 
moderate UC in the Double -blind Acute Phase
 Assess improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) score betw een a low  and high 
dose of MMX mesalamine/mesalazine in children and adolescents a ged 5 -17 years with mild to moderate 
UC in the Double -blind Acute Phase.
Double -blind Maintenance Phase
The secondary objectives of the Double -blind Maintenance Phase are to :
 Assess clinical and endoscopic response to treatment with MMX mesalamine/mesalaz ine betw een a low 
and high dose in children and adolescents aged 5 -17 years who are in remission in the Double -blind 
Maintenance Phase
Shire CONFI DENTIAL Page 16
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
 Assess changes in the DUCS for children and caregivers between a low  and high dose of MMX 
mesalamine/mesalazine in childr en and adolescents aged 5 -17 years who are in remission in the Double -
blind Maintenance Phase
 Assess remission using the PUCAI score betw een a low  and high dose of MMX mesalamine/mesalazine in 
children and adolescents aged 5 -17 years who are in remission i n the Double -blind Maintenance Phase .
Safety
The safety objectives include the evaluat ion of the safety and tolerability of a low  and high dose MMX 
mesalamine/mesalazine in children and adolescents aged 5 -17 years with mild to moderate UC, in the 
Double -blind Acute Phase, the Open -label Acute Phase, and the Double -blind Maintenance Phase.
Rationale:
MMX mesalamine/mesalazine is approved for both the induction of remission in adult patients with mild to 
moderate UC and for maintenance of remission of UC.  N o data are available on the use of MMX 
mesalamine/mesalazine in children and adolescents ; this study aims to evaluate the effect of MMX 
mesalamine/mesalazine in children and adolescents with mild to moderate UC or who are in remission aged 
5-17 years.
Investigational product, dose, and m ode of administration:
 MMX mesalamine/mesalazine, administered orally, randomized in a 1:1 ratio stratified by body weight 
group to the following doses:
 900mg/day or 1800mg/day for subjects w eighing 18 to  23kg
 1200m g/day o r 2400mg/day for subjects w eighing >23 to  35kg
 1800m g/day or 3600mg/day for subjects w eighing >35 to  50kg
 2400m g/day or 4800mg/day for subjects w eighing >50 to  90kg
 MMX mesalamine/mesalazine tablet strengths 300, 600, and 1200mg with matching placebos t o maintain 
the blind between low and high dose groups
Methodology:
This is a prospective study with a Screening Period of 3 to 21days, an 8-week Double -blind Acute Phase, and a 
26-week Double -blind Maintenance Phase.  Each phase includes 2 arms, and subj ects will be randomized to 1 
of 2 doses (low  or high) of MMX mesalamine/mesalazine (900 -4800mg/day, given once daily) at the beginning 
of each phase.  Randomization will be in a 1:1 ratio stratified by body weig ht group. There is an additional 8 -
week, Open -label Acute Phase for subjects who do not achieve a clinical response or who have withdrawn from 
the Double -blind Acute Phase after a minimum of 2 w eeks and, in the investigator’s opinion, have not benefited 
from treatment in the Double -blind Acute Phase.   Clinical response is defined as partial Ulcerative Colitis 
Disease Activity Index (UC-DAI)≤1 (with rectal bleeding=0 andstool frequency ≤1 andPhysician’s Global 
Assessment [ PGA ]=0) at the end of the Double -blind Acute Phase.  In this Open -label Acute Phase, subjects are 
treated w ith the high dose of MMX mesalamine/mesalazine for their we ight group.
At the Baseline Visit (Visit 2): 
 Subjects with partial U C
-DAI ≥2 (with a com bined rectal bleeding and stool frequency score ≥1 and
PGA=1 or 2) andwith mucosal appearance (endoscopy score) =2 or 3 will be eligible to enter the 
Double -blind Acute Phase.
 Subjects with partial UC -DAI ≤1 (with rectal bleeding=0 andstool frequency ≤1 and PGA=0) andwith 
mucos al appearance (endoscopy score)=0 or 1 will be eligible to enter the Double -blind Maintenance 
Phase. 
Shire CONFI DENTIAL Page 17
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subjects with partial UC -DAI score betw een 1 and 2 will not be eligible to enter the Double -blind Acute Phase 
or the Double -blind Maintenance Phase.
A minimum of 1 score each for stool frequency and rectal ble eding must be available in order to randomize 
subjects into either the Double- blind Acute Phase o r the Double- blind Maintenance P hase. Subjects with no 
symptom score data available will be considered screen failures as these symptom score data are used to 
calculate the partial U C-DAI score needed for enrollment .
Subjects who do not meet all the eligib ility criteria for either the Double -blind Acute Phase o r the Double -blind 
Maintenance P hase will be considered screen failures. Subjects may be rescreened after consultation with the 
medical monitor.
Subjects with a clinical response after completion of treatment in either the Double -blind Acute Phase or the 
Open -label Acute Phase will be eligible to enter the Double -blind Maintenance Phase based on partial UC -DAI 
score (ie, without additional endoscopy).
Subjects without a clinical response after completion of acute treatment in the Open -label Acute Phase must be 
withdrawn.
All subjects will have a Screening Visit (Visit 1), and screened subjects who are eligi ble will proceed to the 
Baseline Visit (Visit 2).  Study visits occur at the following time points after the Baseline Visit (Visit 2), 
dependent on the subject’s partial UC -DAI score:
Double -blind Acute Phase : Week 2, Week 4, Week 8 (Double -blind Acute Pha se Withdraw al)
Open -label Acute Phase : Week 2, Week 4, Week 8 (Open -label Acute Phase Withdrawal)
Double -blind Maintenance Phase :  Weeks 2 -4 (investigational product dispensation only), Week 13, Week 26 
(Double- blind Maintenance Phase Withdraw al)
Inclusio n and exclusion criteria:
Inclusion Criteria:
General:
1.Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized 
representative [LAR]) informed consent or assent as applicable to participate in the study.
2.Subject’s p arent/LAR demonstrates an understanding, ability, and willingness to fully comply with study 
procedures and restrictions.
3.Male and female children and adolescents aged 5 -17 years, inclusive, at the Baseline Visit (Visit 2).
4.Body  weight 18 -90kg at the Scree ning Visit (Visit 1) and the Baseline Visit (Visit 2).
5.Male, or non -pregnant, non -lactating female who agrees to comply with any applicable contraceptive 
requirements of the protocol or females of non -childbearing potential.
6.Diagnosed with mild to moderate UC, established by sigmoidoscopy or colonoscopy with compatible 
histology.  Screened subjects may also have an unconfirmed diagnosis of mild to moderate UC; however ,
the diagnosis of mild to moderate UC must have been established by sigmoidoscopy or colon oscopy with 
compatible histology prior to the Baseline Visit (Visit 2).
7.Subject is able to sw allow the investigational product whole.
Double -blind Acute Phase: 
8.Partial UC -DAI score ≥2 (with a com bined rectal bleeding and stool frequency score ≥1 andPGA=1 or 2 ) 
andwith mucos al appearance (endoscopy score)=2 or 3 at the Baseline Visit (Visit 2) , for which 
5-aminosalicylic acid (5-ASA )would be used as part of normal treatment .
Shire CONFI DENTIAL Page 18
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
9.If the subject is on 5 -ASA treatment prior to study entry, then the dose must be stable.  Stable therapy is 
defined as no change in dose, or no initiation of 5 -ASA, from the onset of the current acute flare through 
discontinuation of therapy (required at the Baseline Visit [Visit 2]).  Please see exclusion criterion 2 8for an 
additional 5 -ASA dose -related requirement.
Double -blind Maintenance Phase: 
10.Partial UC-DAI score ≤1 (with rectal bleeding=0 andstool frequency ≤1 andPGA=0) andwith mucosal 
appearance (endoscopy score) =0 or 1 at the Baseline Visit (Visit 2).
Exclusion Criteria:
General:
1.Severe UC (defined by PGA=3) at the Baseline Visit (Visit 2).
2.Crohn’s disease, b leeding disorders, and/or active peptic ulcer disease .
3.Asthma, only if known to be 5 -ASA sensitive.
4.Positive stool culture for enteric pathogens (including Salmonella , Shigella , Yersin i a , Aeromonas , 
Plesiomonas , or Campylobacter ).  Clostridium difficile toxin, ova, or parasites present.
5.Previous colonic surgery.
6.History of hepatic impairment that, in the opinion of the investigator ,may be incompatible w ith 
mesalamine treatment .
7.Moderate to severe renal impairment, in the opinion of the investigator .
8.Immed iate or significant risk of toxic megacolon, in the opinion of the investigator.
9.History of pancreatitis.
10.History of Reye ’s syndrome.
11.Systemic or rectal corticosteroid use withi n 4 w eeks p rior to the Screening Visit (Visit 1).  Topical, 
intranasal, or inha led u se is not exclusionary.
12.Immunomodulator (6 -mercaptopurine, azathioprine) use within 6 weeks prior to the Screening Visit 
(Visit 1).
13.History of biologic (eg, anti -tumor necrosis factor agents, integrin receptor antagonists) within 1 year prior 
to the Screening Visit (Visit 1) . 
14.Antibiotic use wit hin 7 days pri or to the Screening Visit (Visit 1).  
15.Any anti -inflammatory drugs, not including 5 -ASA treatment but including non -steroidal anti -
inflammatory drugs such as aspirin, cyclooxygenase -2 inhibitors or ibuprofen, w ithin 7 days prior to the 
Screening Visit (Visit 1) unless used at over -the-counter levels for <3 days.  How ever, prophylactic use of a 
stable dose of aspirin up to 325mg/day for cardiac disease is permitted.
16.Oral anticoagulant use (with the e xception of subjects who have been on a stable dose of vitamin K 
antagonists such as warfarin for at least 90 days prior to the Screening Visit [Visit 1] and who are medically 
stable).
17.Treatment with anti -diarrheals and/or anti -spasmodics within 3 days pri or to the Screening Visit (Visit 1). 
18.Vaccination/immunization within 21days prior to the Screening Visit (Visit 1).
19.Predisposed to the development of myo -or pericarditis.
20.Previously been randomized into this study and withdrawn.  
Shire CONFI DENTIAL Page 19
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
21.Current or recurrent disease that could affect the action, absorption, or disposition of the investigational 
product, or could affect clinical or laboratory assessments.
22.Current or relevant history of physical or psychiatric illness, any medical disorder that may require 
treatm ent, including surgery, or make the subject unlikely to fully complete the study, or any condition that 
presents undue risk from the investigational product or procedures.
23.Current use of any medication (including over -the-counter, herbal, or homeopathic pr eparations) that could 
affect (improve or w orsen) the condition being studied, or could affect the action, absorption, or disposition 
of the investigational product(s), or clinical or laboratory assessment.  (Current use is defined as use within 
21days of the Screening Visit [Visit 1] , or pharmacokinetic equivalent of 5 half -lives, whichever is longer. )
24.Known or suspected intolerance or hypersensitivity to the investigational product(s) (aminosalicylates 
[5-ASA]) , closely related compounds (including but not limited to salicylates) , or any of the stated 
ingredients. 
25.Known history of alcohol or other substance abuse within the last year.
26.Within 30 days prior to the first dose of investigational product:
-Have used an investigational product
-Have been en rolled in a clinical study (including vaccine studies) that, in the investigator’s opinion, may 
impact this study.
Double -blind Acute Phase:
27.Mucosal appearance (defined by endoscopic score=0 or 1) based on central reading or local reading (if 
central read ing is not available) at the Screening Visit (Visit 1) or Baseline Visit (Visit 2).
28.Current relapse on a 5 -ASA dose higher than the low  dose tested in the study (900mg for subjects weighing 
18 to 23kg, 1200mg for subjects weighing >23 to 35kg, 1800mg for subjects weighing >35 to 50kg, 
and 2400mg for subjects weighing >50 to 90kg).
29.Acute flare with onset >6 weeks prior to the Baseline Visit (Visit 2) if being treated with 5 -ASA for the 
flare.  There is no limit to the onset of flare prior to the Baseline Visit (Visit 2) if the flare is untreated.
Double -blind Maintenance Phase:
30.Mucosal appearance (endoscopic score)=2 or 3 based on central reading or local reading (if central reading 
is not available) at the Screening Visit (Visit 1) or Baseline Visit (Vi sit 2).
Re-randomization:  Subjects with a clinical response ,ie, partial UC-DAI ≤1 (defined as rectal bleeding=0 and
stool frequency ≤1 andPGA=0) after completion of treatment in either the Double -blind or the Open -label 
Acute Phases will be eligible for re- randomization into the Double -blind Maintenance Phase provided they st ill 
meet all Baseline (Visit 2) inclusion and exclusion criteria (where re- assessed).  
Note that an additional eligibility endoscopy is not required for entry into the Double -blind Maintenance Phase 
for subjects who achieve a clinical response after compl etion of treatment in either the Double- blind Acute 
Phase or the Open -label Acute Phase.
Subjects eligible for either the Double -blind A cute or the Double -blind M aintenance Phase can be re-
randomized if they initially failed randomization for the followin g reasons: incorrect use of IVRS, late or 
missing central lab oratory or endoscopy results, or other reasons of this type as long as they meet inclusion and 
exclusion criteria. Re -random ization can only take place after consultation with the medical monitor.
Subjects may be re- randomized into the Double -blind Maintenance Phase if they turned 18 during participation 
in either Acute Phase of the study.
Shire CONFI DENTIAL Page 20
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Maximum duration of subject involvem ent in the study:
 Planned duration of screening period: 3 to 21days
 Planned duration of treatment period: up to 42 w eeks
 Planned duration of follow -up: 7 days
Endpoints and statistical analysis:
Prim ary Efficacy Endpoints 
Double -blind Acute Phase:
The primary efficacy endpoint for the Double -blind Acute Phase is defined as the proportion of subjects w ith a 
clinical resp onse (defined as partial UC -DAI ≤1 w ith rectal bleeding=0 andstool frequency ≤1andPGA=0) at 
Week 8.  This endpoint will be compared betw een treatment arms using a continuity -corrected chi-squared test.
Double -blind Maintenance Phase:
The primary efficac y endpoint for the Double -blind Maintenance Phase is defined as the proportion of subjects 
who have maintained a clinical response (defined as partial UC -DAI ≤1 w ith rectal bleeding=0 andstool 
frequency ≤1 andPGA=0) at Week 26.  This endpoint will be com pared betw een treatment arms using a 
Cochran -Mantel -Haenszel (CMH) test stratifying by Week 8 responder status.
Secondary Efficacy Endpoints 
Double -blind Acute Phase:
The proportion of subjects w ith a clinical and endoscopic response at Week 8, defined as UC-DAI ≤2 w ith 
rectal bleeding=0 andstool frequency ≤1andPGA=0, andwith mucosal healing (endoscopy score ≤1) 
based on central reading.  In addition, there must be at least a 1 -point reduction in endoscopy score from 
baseline.  This endpoint will be compare d betw een treatment arms using a continuity -corrected chi -squared 
test.
The proportion of subjects w ith a clinical and endoscopic response at Week 8, defined as UC -DAI ≤2 w ith 
rectal bleeding=0 andstool frequency ≤1andPGA=0, andwith mucosal healing (en doscopy score ≤1) 
based on local reading.  In addition, there must be at least a 1 -point reduction in endoscopy score from 
baseline. This endpoint will be compared between treatment arms using a continuity -corrected chi -squared 
test.
The change in the DUCS score from baseline to Week 8 of the Double -blind Acute Phase.  This endpoint 
will be compared betw een treatment arms using an analysis of covariance, including the baseline DUCS 
score as a covariate in the model.
The percentage of subjects with an improv ement (change of ≥20 points) in PUCAI score from baseline to 
Week 8 of the Double -blind Acute Phase.  This endpoint will be compared betw een treatment arms using a 
continuity -corrected chi -squared test.
Double -blind Maintenance Phase:
The proportion of sub jects who have maintained a clinical and endoscopic response at Week 26, defined as 
UC-DAI ≤2 w ith rectal bleeding=0 andstool frequency ≤1andPGA=0, andwith mucosal healing 
(endoscopy score ≤1) based on central reading.  This endpoint will be compared b etween treatment arms 
using a CMH test stratifying by Week 8 responder status.
The proportion of subjects who have maintained a clinical and endoscopic response at Week 26, defined as 
UC-DAI ≤2 w ith rectal bleeding=0 andstool frequency ≤1andPGA=0, andwith mucosal healing 
(endoscopy score ≤1) based on local reading.  This endpoint w ill be compared betw een treatment arms 
using a CMH test stratifying by Week 8 responder status.
The change in the DUCS score from Double -blind Maintenance Phase Week 0 to Week 26.  This endpoint 
will be compared betw een treatment arms using an analysis of covariance, including the DUCS score at 
Double -blind Maintenance Phase Week 0 and Week 8 responder status as covariates in the model.
Shire CONFI DENTIAL Page 21
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The percentage of subjects in remission ( PUCAI <10) at Double- blind Maintenance Phase Week 26.  This 
endpoint will be compared between treatment arms using a CMH test stratifying by Week 8 responder 
status.
Sensitivity Analyses of the Prim ary Endpoint
The follow ing sensitivity analyses will be performed for both the Double -blind Acute and the Double -blind 
Maintenance Phase primary endpoints:
A modified clinical response, defined as partial UC -DAI≤1 with rectal bleeding=0 andstool frequency ≤1 
will be analyzed in a similar way to the primary endpo int analysis in order to investigate the effect of 
removing the PGA component from the responder definition.
An observed -case analysis will be performed, where data from those who completed Week 26 and those 
who withdrew  from  the study early and  are prese nted and analyzed separately, using a similar analysis to 
the primary endpoint.  
A complete- case analysis, where subjects who withdraw early from the study will be excluded, w ill be 
performed in a similar way to the primary endpoint analysis.
A last obser vation carried forward analysis, using data from the final on -treatment assessment, will be 
performed in a similar way to the primary endpoint analysis.
Logistic modeling will be conducted to investigate the effect of doses in mg/kg on the clinical respons e in 
the Double -blind Acute and Double -blind Maintenance Phases.  
Safety Endpoints 
Adverse events (AEs) w ill be coded using the Medical Dictionary for Regulatory Activities.   Treatment-
emergent AEs (TEAEs) will be defined in the 
statistical analysis plan .  The number of events, incidence, and 
percentage of TEAEs will be presented by treatment arm (ie, low  or high dose), and overall, by system organ 
class, and by preferred term.  Treatment -emergent AEswill be further summarized by treatment arm for severi ty 
and relationship to investigational product.  T reatment -emergent AEs related to investigational product, TEAEs 
leading to withdrawal, serious AEs, and deaths will be summarized by treatment arm.
Clinical laboratory tests and vital signs, and their chang es from baseline will be summarized by treatment arm 
and visit.  
Sample Size Justification 
The sample size of 80 subjects originally selected for each of the Double -blind Acute and Double- blind 
Maintenance Phases waschosen based on both practical consid erations and on agreement with the United States 
Food and D rug Administration .
Shire CONFIDENTIAL Page 25
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Table 1: Double - blind Acute Phase
Visit 1
(Screening)Recommended 
Telephone 
calla2
(Baseline)3b3.1 3.2c, d, e, f6g
Week /MonthhDay –21 to –3 Day –7to ⎼4 Week 0 Week 2 Week 4 Week 8/Withdrawal Follow -up
mRectal bleeding, stool frequency, DUCS, and Overall Current Health e -diary entry is completed once a day before bedtime every day from the evening of the Screening Visit 
(Visit 1), preferably for at least the 3 days immediately prior to the Baseline Visit (Visit 2).  Rectal bleeding, stool freq uency, DUCS and Overall Current Health e -diary entry is 
completed once a day before bedtime for the 5 days immediately prior to Visits 3, 3.1, and 3.2 of the Double -blind Acute Phase.
nGlobal Change in Health to be completed by caregivers of children aged 5 -10 years and by children aged 11 -17 years; IMPACT III to be completed by children aged 8 -17 year s 
only (see Section 7.2.4.1 ).
oThe average stool frequency and rectal bleeding scores will be calculated and available to the investigator through a report from the e -diary provider.
pComponents of the partial UC -DAI.
qComponents of the modified full UC-DAI.
rFor subjects entering the Double -Blind Acute Phase only: Subjects with an unconfirmed diagnosis of UC must have endoscopy performed during the Screening Visit (Visit 1).  
Subjects with a previously confirmed diagnosis must have endoscopy at the Screening Visit (Visit 1) or at the Baseline Visit (Visit 2) if endoscopy has not been performed within 
21days prior to the Screening Visit (Visit 1).
sOnly for subjects continuing into the Open -label Acute or Double - blind Maintenance Phase.
Shire CONFIDENTIAL Page 27
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Table 2: Open -label Acute Phase
Visit Recommended 
Telephone calla4 4.1 4.2b, c, d, e6f
WeekgDay ⎼7 to ⎼4 Week 2 Week 4 Week 8/Withdrawal Follow -up
Investigational product 
dispensed  m
Investigational product collected 
and compliance calculated  
Adverse events     
Concomitant medication    
Re-randomization (subjects 
entering Double -blind 
Maintenance Phase only)
Abbreviations: DUCS=Daily Ulcerative Colitis Scale for children and caregivers; e -diary=electronic diary; IRT= interactive response technology; PGA=Physician’s Global 
Assessment; PUCAI=Pediatric Ulcerative Colitis Activity Index; UC -DAI=Ulcer ative Colitis Disease Activity Index.
a Approximately 4 to 7 days prior to Visit 4 and prior to each subsequent visit (Visits 4.1 and 4.2), it is recommended that site staff telephone th e subject or the subject’s caregiver 
to remind them to enter UC -DAI sy mptoms (rectal bleeding and stool frequency) into the e -diary every night, even if the subject has no symptoms.
bSubjects will continue into the Double -blind Maintenance Pha se if partial UC -DAI ≤1 (with rectal bleeding=0 andstool frequency ≤1 andPGA=0) and are eligible to continue 
into the Double -blind Maintenance Phase.
c Subjects will be withdrawn from the study if they have not achieved a partial UC-DAI ≤1 (with rectal b leeding=0 andstool frequency ≤1 andPGA=0).
dThis will be the final visit for subjects not continuing into the Double -blind Maintenance Phase.
eThe Baseline Visit (Visit 2) does not need to be repeated for subjects entering the Double -blind Maintenance Phase at the end of the Open -label Acute Phase.  Visit 4.2 will be 
considered the Week 0 visit for the Double -blind Maintenance Phase.
fFollow -up assessment in this phase applies only to subjects who are discontinuing the study; may be performed via telep hone call within 7 days of the last dose of investigational 
product.
gA visit window of 3 days is permitted for all study visits.
hThe serum pregnancy test will be performed for all female subjects ofchildbearing potential at Week 8/Withdrawal (Visit 4.2). Urine pregnancy tests will be performed at all 
other visits.
iRectal bleeding, stool frequency, DUCS, and Overall Current Health e -diary entry is completed once a day before bedtime every day for 5 days immediately prior to Visits 4, 4.1 
and4.2 of t he Open -label Acute Phase.
jThe average stool frequency and rectal bleeding scores will be calculated and available to the investigator through a report from the e -diary provider.
kComponents of the partial UC -DAI.
lCom ponents of the modified full UC -DAI.
mOnly for subjects continuing into the Double -blind Maintenance Phase.
Shire CONFIDENTIAL Page 29
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Table 3: Double -blind Maintenance Phase
Visit 1
(Screening )aRecommended 
Telephone 
callb2
(Baseline )a5 5.1 5.2 6c
Day/MonthdDay –21 to –
3Day ⎼7 to ⎼4 Week 0 Weeks 2 -4 Week 13 Week 26/ 
WithdrawalFollow -up
Review DUCS instructions, abilit y 
to read and understand e -diary 
with subject/caregiver
Subject/caregiver e -diary entry: 
rectal bleeding, stool frequency, 
DUCS ,and Overall Current 
Healthh   
Assessment of e -diary compliancea
Global Change in Healthi
IMPACT IIIi 
PUCAI (where applicable)  
Average stool frequency j, k, l  
Average rectal bleedingj, k, l  
PGAk, l 
Endoscopy (flexible 
sigmoidoscopy or colonoscopy) 
for study eligibilityd, l, m 
Endosc opy (flexible 
sigmoidoscopy or colonoscopy), 
where possiblel
IRT entry     
Calculate partial UC -DAI  
Investigational product dispensed   
Investigational product collected 
and compliance calculated  
Adverse even ts       
Concomitant medication     
Shire CONFIDENTIAL Page 31
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
1. BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Ulcerative colitis (UC) is a serious chronic inflammatory  disease of the colon and rectum.  The 
major clinical feature is bloody  diarrhea.  While an acute attack can occasionally  be fatal, the 
characteristic course for most patients is one of remissions and exacerbations over a number of 
years.  Life expectancy  after recovery  from a first attack is unchanged; however, morbidit y can 
be long -lasting and may  be associated with various extra -intestinal and late complications.  
Extensive disease is observed in 60 -80% of all cases when UC onset is in childhood, which is 
twice as often as in adults.  Extensive disease results in a worse disease course, since disease 
course is correlated t o disease severit y.  In children, 30 -40% colectomy  rates are seen at 10 years 
compared to 20% in adults with UC ( Turner et al. 2012 ).  Children may  also develop unique and 
troublesome complications, including growth failure and delay ed pubert y.  Although infrequent 
and geographicall
y dispersed, UC has been reported as earl y as infancy.  Most children with UC, 
however, are diagnosed in late childhood and adolescence.  The peak incidence of inflammatory  
bowel di sease occurs in patients between the ages of 15 and 25 years.  Approximately  20% of 
patients with UC present before the age of 20 y ears ( Mendeloff and Calkins 1988 ).  There are 
approximately  50,000 children c urrently  with UC in the US, primarily  post -pubertal.  
Clinical pediatricians agree that mesalamine has a role in therap y of UC in children, and 
pediatric gastroenterology  guidelines contain reference to mesalamine therapy  in UC.  The side 
effect profile o f mesalamine is broadly  similar to placebo, and there are no indications from the 
literature that use of mesalamine in children is associated with a higher incidence of side effects.  
The only  acetyl-5-aminosalicy lic acid ( 5-ASA ) /mesalamine product that i s currentl y licensed in 
the US for use in children/adolescents (aged 5 years and older with UC) and that is available in 
non-tablet formulation is balsalazide (C OLAZAL, Salix Pharmaceuticals, Inc ) capsules.  
Balsalazide is a prodrug that is enzy maticall y cleaved in the colon to produce mesalamine.  
Capsule contents can be sprinkled on apple sauce if the capsules are too big to swallow.
The approval of 5 -ASA products in other countries for use on children/adolescents varies.
1.2 Product Background and Clinical Information
Commercially  available Multi -Matrix Sy stem ( MMX) mesalamine/mesalazine is a novel, high -
strength formulation of 5 -ASA (1.2g of mesalamine/mesalazine per tablet), which uses MMX 
technology  designed to release 5 -ASA throughout the colon.  For the purpose of this study , 2 
pediatric formulations (300mg and 600mg tablets) were developed, which are smaller than the 
commerciall y available product.
The patented MMX delivery  system utilizes hy drophilic and lipophilic matrices enclosed within 
a gastro -
resistant, pH- dependent coating to facilitate prolonged exposure of the colonic mucosa 
to 5-ASA.  The gastro- resistant coating that covers the multi -matrix core delay s release of 
5-ASA until the tablet is exposed to approximately  pH of 7.0 or higher, normal ly in the terminal 
ileum, at which time the coating disintegrates.
Shire CONFIDENTIAL Page 32
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Due to the presence of the hy drophilic matrix, the tablet core is designed to swell upon exposure 
to intestinal fluid (in a manner similar to that of a sponge exposed to water) to form a vi scous gel 
mass.  This viscous gel mass is expected to slow the diffusion of the active drug from the tablet 
core into the colonic lumen.  As the tablet and its surrounding gel mass progress through the 
colon, pieces of the gel mass are expected to graduall y break away from the core.  This allows 
release of some 5- ASA in proximity  to the colonic mucosa.  In addition, literature suggests that 
the hy drophilic matrix may  also adhere to the colonic mucosa, thus delivering 5 -ASA to its site 
of action.
The lipophi lic matrix, together with 5 -ASA, is interspersed within the hy drophilic matrix 
creating a partiall y hydrophobic environment, which slows the penetration of aqueous fluids into 
the tablet core.  This is expected to slow the drug dissolution and provide a fu rther extended 
release of the active medication, potentially  prolonging therapeutic activity .
Alway s refer to the latest version of the MMX Mesalazine (Mesalamine) Investigator’s Brochure 
for the overall risk/benefit assessment and the most accurate and cu rrent information regarding 
the drug metabolism, pharmacokinetics, efficacy  and safet y of MMX mesalamine/mesalazine. 
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
MMX mesalamine/mesalazine is approved for both the induction of remission in adult pa tients 
with mild to moderate UC and for maintenance of remission of UC.  Currently , limited data are 
available on the safet y and efficacy of MMX mesalamine/mesalazine in children and adolescents 
with UC.  
This study , a Pediatric Research Equity  Act post-approval commitment with United States (US) 
Food and Drug Administration ( FDA ), is designed to find the appropriate dosage of MMX 
mesalamine/mesalazine for once -daily  dosing across a range of weight groups, in children and 
adolescents aged 5- 17 years with m ild to moderate UC or who are in remission. As improved 
compliance may  be achieved with once- daily  dosing, a better overall treatment benefit may  be 
obtained compared to existing alternatives for pediatric patients.
The data from this study  will:
 Determine whether MMX mesalamine/mesalazine is safe and effective for use in children 
and adolescents (aged 5 -17 years) with mild to moderate UC or who are in remission.
 Aid in selection of appropriate doses in the pediatric population.
The study  allows all subjects to receive active MMX mesalamine/mesalazine. The doses for the 
study  were determined from pharmacokinetic modeling using data from the SPD476 -112 study , 
a pharmacokinetic stud y in children and adolescents with mild to moderate UC. 
The inclusion of plac ebo and standard of care arms were considered in the design of this stud y.  
The use of placebo was considered impractical given the alternative treatments currentl y 
available to children and adolescents with UC. 
Shire CONFIDENTIAL Page 33
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Asstandard ofcare varies andthere isno standard formulation or dose of 5- ASA licensed and 
approved across regions, a standard of care/co mparator arm was not included.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the Double -blind Acute Phase of the study  is to assess clinical response 
to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 
5-17 years with mild to moderate UC.
The primary  objective of the Double -blind Maintenance Phase of the study  is to assess 
maintenance of clinical response to MMX mesalamine/mesalazine between a low and high dose 
in children and adolescents aged 5 -17 years who are in remission.
2.2.2 Secondary Objectives
Double -
blind Acute Phase
The secondary  objectives of the Double- blind Acute Phase are to :
 Assess clinical and endoscopic response to treatment with MMX mesalamine/mesalazine 
between a low and high dose in children and adolescents aged 5 -17 years with mild to 
moderate UC in the Double- blind Acute Phase
 Assess changes in the Daily  Ulcerative Colitis Scale ( DUCS )for child ren and caregivers 
between a low and high dose of MMX mesalamine/mesalazine in children and adolescents 
aged 5 -17 years with mild to moderate UC in the Double -blind Acute Phase
 Assess improvement in the Pediatric Ulcerative Colitis Activity  Index ( PUCAI ) score 
between a low and high dose of MMX mesalamine/mesalazine in children and adolescents 
aged 5 -17 years with mild to moderate UC in the Double -blind Acute Phase .
Double -blind Maintenance Phase
The secondary  objectives of the Double-blind Maintenance Phas e are to :
 Assess clinical and endoscopic response to treatment with MMX mesalamine/mesalazine 
between a low and high dose in children and adolescents aged 5 -17 years who are in 
remission in the Double- blind Maintenance Phase
 Assess changes in the DUCS for children and caregivers between a low and high dose of 
MMX mesalamine/mesalazine in children and adolescents aged 5 -17 years who are in 
remission in the Double- blind Maintenance Phase
 Assess remission using the PUCAI score between a low and high dose of MM X 
mesalamine/mesalazine in children and adolescents aged 5 -17 years who are in remission 
in the Double-blind Maintenance Phase.
Shire CONFIDENTIAL Page 35
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
In this Open -label Acute Phase, subjects are treated with the high dose of MMX 
mesalamine/mesalazine for their weight group.
Subjects with a clinical response after completion of treatment in either the Double -blind Acute 
Phase or the Open -label Acute Phase will be eligible to enter the Double-blind Maintenance 
Phase base d on partial UC -DAI score (ie ,without additional endoscopy ).  
Subjects without a clinical response after completion of treatment in both the Double -blind 
Acute Phase and the Open -label Acute Phase will not be eligible to enter the Double- blind 
Maintenanc e Phase and must be withdrawn.
Subjects may  enter the Double -blind Maintenance Phase directl y following the Baseline Visit 
(Visit 2) if they  have a partial UC -DAI ≤1 (with rectal bleeding=0 andstool frequency  ≤1 and
PGA=0) andwith mucos al appearance (end oscopy  score)=0 or 1 
at that visit.
MMX mesalamine/mesalazine is dosed once dail y by mouth. The selection of doses in this study  
is based on an approximate average of 43mg/kg for the low dose and 85mg/kg for the high dose 
in the 3 lower weight groups (18 t o 23kg, >23 to 35kg and >35 to 50kg).  These doses were 
selected based on standard of care dosing for other 5 -
ASA products in the pediatric population 
and pharmacokinetic dosing results.  The dosing for the highest weight group (>50 to 90kg) is 
based o n adult UC experience.
This study  will be conducted in children and adolescents (aged 5- 17 years) to collect data on the 
safet y and efficacy of MMX mesalazine/mesalamine in this population.  This study  is a Pediatric 
Research Equity  Act post-approval commi tment with the US FDA.
Minimum enrollment criteria have been agreed with FDA as follows, based on subject weight 
group ; these are summarized in Table 
4.
Table 4: Minimally Required Number of Subjects per Weight Group
Weight Group Number of Subjects in Combined Low and High Dose a
18 to 23kg 2
>23 to 35kg 12
>35 to 50kg 18
>50 to 90kg 36
aRandomization will be stratified by weight group with the aim of creating balance between the 2 dose groups within a weight 
group.
Shire CONFIDENTIAL Page 36
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Figure 1:Study Design Flow Chart
PGA=Physician’s Global Assessment ; UC-DAI=Ulcerative Colitis Disease Activity Index
aSubjects with partial UC-DAI ≥2 (with a combined rectal bleeding and stool frequency score ≥1 andPGA=1 or 2) andwith 
mucosa l appearance (endoscopy score)=2 or 3 .
bSubjects with partial UC -DAI ≤1(with rectal bleeding=0 and stool frequency ≤1 andPGA=0) andwith mucos al appeara nce 
(endoscopy score)=0 or 1 .
Note s: Solid boxes indicate study phases. Dashed ellipses indicate decision points. 
Subjects will initially be randomized into either the 8 -week Double -blind Acute Phase or the 26 -week Double -blind Maintenance 
Phase based on partial UC -DAI and mucosal appearance scores as defined in Section 7.1.1.2 . Subjects who do not achieve a 
clinical response or who have withdrawn from the Double -blind Acute Phase after a minimum of 2 weeks and, in the 
investigator’s opinion, have not bene fited from treatment in the Double -blind Acute Phase may enter the Open -label Phase , see 
Section 7.1.3 . Subjects without a clinical response after completion of acute treatment in the Open - label Acute Phase must be 
withdrawn.

Shire CONFIDENTIAL Page 37
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
3.2 Duration and Study Completion Definition
The last subject contact for this study  is the follow -up assessment (Visit 6).
The maximum duration of participation for a subject following randomization is expected to be 
approximately  42weeks.  The study  will be completed in approximately  5 years.
The Study  Completion Date is defined as the date the final subject, across all sites, completes 
their final protocol -defined assessment.  Please note that this includes the follow -up visit or 
contact, whichever is later.  The Study  Completion Date i s used to ascertain timing for study  
results posting and reporting.
3.3 Sites and Regions
It is anticipated that sites in approximately  8countries will participate in this study .  These 
countries are located in North America, Europe, and the Middle East.  App roximately  48sites 
are expected to enroll subjects into the study .
4. STUDY POPULATION
Each subject and/or caregiver must participate in the informed consent process and provide 
written informed consent/assent before an y procedures specified in the protocol are performed.
4.1
Inclusion Criteria
The subject will not be considered eligible for the study  without meeting all of the criteria below.
General:
1. Ability  to voluntaril y provide written, signed, and dated (personally or via a legally  
authorized representative [LAR ]) informed consent or assent as applicable to participate in 
the study .
2. Subject’s parent/LAR demonstrates an understanding, ability, and willingness to fully 
comply  with study  procedures and restrictions.
3. Male and female children and adolescents aged 5-17 years, inclusive, at the Baseline Visit 
(Visit 2).
4. Body weight 18 -90kg at the Screening Visit (Visit 1) and the Baseline Visit (Visit 2).
5. Male, or non- pregnant, non -lactating female who agrees to comply  with any  applicable 
contraceptive requirements of the protocol or females of non -childbearing potential.
6. Diagnosed with mild to moderate UC, established by  sigmoidoscopy  or colonoscopy  with 
compatible histology .  Screened subjects may  also have an unconfirmed diagnosis of mild 
to moderate UC; however , the diagnosis of mild to moderate UC must have been 
established by  sigmoidoscopy  or colonoscopy  with compatible histology  prior to the 
Baseline Visit (Visit 2).
Shire CONFIDENTIAL Page 38
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
7. Subject is able to swallow the investigational product whole.
Double -blind Acute Phase: 
8. Partial UC -DAI score ≥2 ( with a combined rectal bleeding andstool frequency  score ≥1 
and PGA=1 or 2 ) andwith mucosal appearance (endoscopy  score)=2 or 3 at the Baseline 
Visit (Visit 2) , for which 5- ASA would be used as part of normal treatment . 
9. If the subje ct is on 5
-ASA treatment prior to study  entry , then the dose must be stable.  
Stable therap y is defined as no change in dose, or no initiation of 5 -ASA, from the onset of 
the current acute flare through discontinuation of therap y (required at the Baseline Visit; 
Visit 2).  See exclusion criterion 28 for an additional 5-ASA dose- related requirement.
Double -blind Maintenance Phase: 
10. Partial UC-DAI ≤1 (with rectal bleeding=0 andstool frequency  ≤1 andPGA=0 ) andwith 
mucos al appearance (endoscopy  score)=0 or 1 at the Baseline Visit (Visit 2). 
4.2
Exclusion Criteria
Subjects are excluded from the study  if an y of the followi ng exclusion criteria a re met. 
General:
1. Severe UC (defined b y PGA=3) at the Baseline Visit (Visit 2).
2. Crohn’s disease, bleeding disorders, and/or active peptic ulcer disease .
3. Asthma, only  if known to be 5 -ASA sensitive.
4. Positive stool culture for enteric pathogens (including Salmonella, Shigella , Yersinia , 
Aeromonas , Plesiomonas , or Campylobacter ).  Clostridium difficile toxin, ova, or parasites 
present.
5. Previous colonic surgery .
6. H istory  of hepatic impairment that, in the opinion of the investigator, may  be incompatible 
with mesalamine treatment .
7. Moderate to severe renal impairment, in the opinion of the investigator.
8. Immediate or significant risk of toxic megacolon, in the opinion of the investigator.
9. History  of pancreatitis.
10. History  of Rey e’s syndrome.
11. Systemic or rectal cortic osteroid use within 4 weeks prior to the Screening Visit (Visit 1).  
Topical, intranasal, or inhaled use is not exclusionary .
12. Immunomodulator (eg, 6 -mercaptopurine, azathioprine) use within 6 weeks prior to the 
Screening Visit (Visit 1).
13. History  of biologi c (eg, anti -tumor necrosis factor agents, integrin receptor antagonists) 
within 1 y ear prior to the Screening Visit (Visit 1) .
Shire CONFIDENTIAL Page 39
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
14. Antibiotic use within 7 days prior to the Screening Visit (Visit 1).  
15. Any anti- inflammatory  drugs, not including 5- ASA treatment but including non -steroidal 
anti-inflammatory  drugs such as aspirin, cy cloox ygenase -2 inhibitors or ibuprofen, within 
7days prior to the Screening Visit (Visit 1) unless used at over
-the-counter levels for 
<3days.  However, prophy lactic use of a stable dose of aspirin up to 325mg/day  for 
cardiac disease is permitted.
16. Oral anticoagulant use (with the exception of subjects who have been on a stable dose of 
vitamin K antagonists such as warfarin for at least 90 days prior to the Screening Visit 
[Visit 1] and who are medically  stable).
17. Treatment with anti-diarrheals and/or anti- spasmodics within 3 day s prior to the Screening 
Visit (Visit 1). 
18. Vaccination/immunization within 21 days prior to the Screening Visit (Visit 1).
19. Predisposed to the development of my o-or pericarditis.
20. Previously  been randomized into this study  and withdrawn.  
21.
Current or recurrent disease that could affect the action, absorption, or disposition of the 
investigational product, or could affect clinical or laboratory assessments.
22. Current or relevant history  of phy sical or ps ychiatric illness, any medical disorder that may 
require treatment, including surgery , or make the subject unlikely  to full y complete the 
study , or an y condition that presents undue risk from the investigational product or 
procedures.
23. Current use of an y medication (including over -the-counter, herbal, or homeopathic 
preparations) that could affect (improve or worsen) the condition being studied, or could 
affect the action, absorption, or disposition of the investigational product(s), or clinical or 
laboratory  assessment.  (Current use is defined as use within 21 days of the Screening Visit 
[Visit 1] , or pharmacokinetic equivalent of 5 half -lives, whichever is longer .)  See 
Section 5(Prior and Concomitant Treatment) for a list of prohibited and restricted 
medications.  
24. Known or suspected intolerance or h
ypersensitivity to the investigational product(s) 
(aminosalicy lates eg, 5 -ASA), closel y related compounds (including but not limited to 
salicy lates), or any  of the stated i ngredients. 
25. Known history  of alcohol or other substance abuse within the last y ear.
26. Within 30 day s prior to the first dose of investigational product:
 Have used an investigational product
 Have been enrolled in a clinical study  (including vaccine studies ) that, in the 
investigator’s opinion, may  impact this study .
Shire CONFIDENTIAL Page 40
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Double -blind Acute Phase: 
27. M ucosal appearance (defined by  endoscopic score=0 or 1) based on central reading or local 
reading (if central reading is not available) at the Screening Visit (Visit 1 ) or Baseline Visit 
(Visit 2).
28. Current relapse on a 5 -ASA dose higher than the low dose tested in the study (900mg for 
subjects weighing 18 to 23kg, 1200mg for subjects weighing >23 to 35kg, 1800mg for 
subjects weighing >35 to  50kg, and 2400mg for subje cts weighing >50 to  90kg).
29. Acute flare with onset >6 weeks prior to the Baseline Visit (Visit 2) if being treated with 5 -
ASA for the flare.  There is no limit to the onset of flare prior to the Baseline Visit (Visit 2) 
if the flare is untreated.
Double -blind Maintenance Phase: 
30. Mucosal appearance (endoscopic score)=2 or 3 based on central reading or local reading (if 
central reading is not available) at the Screening Visit (Visit 1) or Baseline Visit (Visit 2).
4.3 Re-randomization
Subjects with a clinical res ponse ,ie, partial UC -DAI ≤1 (with rectal bleeding=0 andstool 
frequency ≤1 andPGA=0) after completion of treatment in either the Double -blind or the Open -
label Acute Phases will be eligible for r e-randomization into the Double -blind Maintenance 
Phase pro vided they  still meet all Baseline Visit (Visit 2) inclusion and exclusion criteria (where 
re-assessed).  
Note that an additional eligibility  endoscop y is not required for entry  into the Double -blind 
Maintenance Phase for subjects who achieve a clinical r esponse after completion of treatment in 
either the Double -blind Acute Phase or the Open -label Acute Phase.
Subjects eligible for either the Double -blind Acute or the Double- blind Maintenance Phase can 
be re -randomized if they  initially  failed randomizatio n for the following reasons: incorrect use of 
IVRS, late or missing central laboratory  or endoscopy  results, or other reasons of this ty pe as 
long as they  meet inclusion and exclusion criteria. Re -randomization can only  take place after 
consultation with t he medical monitor.
Subjects may  be re -randomized into the Double -blind Maintenance Phase if they  turned 18 years 
ofageduring participation in either Acute Phase of the study .
4.4 Reproductive Potential
4.4.1 Female Contraception
Sexually  active females of childbe aring potential must be using an acceptable form of 
contraception.  Females of childbearing potential must be advised to use acceptable 
contraceptives throughout the study period and for 30 days following the last dose of 
investigational product.  If hormo nal contraceptives are used they  should be administered 
according to the package insert.  
Shire CONFIDENTIAL Page 41
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Females ofchildbearing potential who arenotcurrently sexually  active must agree to use 
acceptable contraception, as defined below, if they become sexually  active d uring the period of 
the study  and 30 day s following the last dose of investigational product. 
All female subjects of childbearing potential must have a negative serum beta-human chorionic 
gonadotropin ( -HCG )pregnancy test at the Screening Visit (Visit 1 ) and prior to randomization .  
Female subjects of childbearing potential must abstain from sexual activity that could result in 
pregnancy  or agree to use acceptable methods of contraception.  Abstinence can only  be 
accepted if this is true abstinence in li ne with the preferred and usual lifestyle of the subject.
Acceptable methods of contraception are:
 Intrauterine devices plus condoms
 Double
-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
 Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the Screening Visit (Visit 1), plus condoms.  Note:  if subject 
becomes sexually  active during the study , they  must use 1 of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
4.5 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care b y the physician or at the institution.  The inv estigator or sponsor may  
withdraw the subject at any  time (eg, in the interest of subject safet y).  The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational pr oduct is discontinued, regardless of the reason, the evaluations listed for the 
Withdrawal Visit (Visits 3.2, 4.2, or 5.2, depending on the phase) are to be performed as 
completely  as possible.  Whenever possible, all discontinued subjects should also unde rgo the 
protocol -specified follow -up.  Comments (spontaneous or elicited) or complaints made by  the 
subject must be recorded in the source documents.  The reason for termination, date of stopping 
investigational product, and the total amount of investigati onal product taken must be recorded in 
source documents.
Subjects who discontinue will not be replaced. 
4.5.1 Reasons for Discontinuation
The reason for withdrawal must be determined b y the investigator and recorded in th e subject’s 
medical record and i n the electronic case report form ( eCRF ).  If a subject is withdrawn for more 
than 1 reason, each reason should be documented in the source document and the most clinically  
relevant reason should be entered in the eCRF.
Shire CONFIDENTIAL Page 42
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Reasons for discontinuation include but are not limited to:
 Adverse event
 Protocol violation
 Withdrawal by  subject
 Lost to follow -up
 Lack of efficacy
 Other (if “Other” is selected, the investigator must provide further details).
4.5.2 Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact).  At least 1 of 
these documented attempts must include a written communication sent to th e subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations and return any unused investigational product.
In addition to the 3 attempts made to prevent su bjects from being lost to follow -up during the 
conduct of the stud y, Shire’s plan is to regularl y evaluate each site for missing data. Any trends 
will be identified and addressed with specific sites should they  emerge. Issues leading to missing 
data will be identified and retraining of the site and support for the site will be implemented as 
appropriate. 
5. PRIOR AND CONCOMITAN T TREATMENT
All non- study  treatment including but not limited to herbal treatments and vitamins received 
within 21days prior to th e Screening Visit (Visit 1) (or pharmacokinetic equivalent of 
5half-lives, whichever is longer) and through the final study  contact (including protocol- defined 
follow-up period) must be recorded i n the appropriate eCRF page.
5.1 Prior Treatment
Prior treatmen t given for the subject’s UC should be recorded for the year prior to the Screening 
Visit (Visit 1), where available.  All other prior treatment, including but not limited to herbal 
treatments and vitamins, received within 21days of the date of first dose of investigational 
product must be recorded.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
investigational product and the end of the follow -up period, inclusive.  Concomitant treatmen t 
information must be recorded i n the appropriate eCRF page.
Shire CONFIDENTIAL Page 43
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
During the Screening Visit (Visit 1), the subject must remain on their current 5 -ASA medication 
for UC (if applicable) at a stable dose until the Baseline Visit (Visit 2), at which time current 
treatment must be discontinued.
5.3 Prohibited Treatment 
Table 5 details the common prior treatments that are excluded medications for this study . 
Table 5: Common Prior Excluded Treatments
Minim um Tim e Before Screening
Treatm ent 3 days 7 days 21days 4 weeks 6 weeks No Use Permitted
Anti-diarrheals and/or 
anti-spasmodicsaX
AntibioticsaX
Anti-inflammatory drugsa, b, cX
Vaccination/immunization X
Systemic or rectal 
corticosteroidsX
Immunomodulators X
Oral anticoagulantsbX
Biologics 1 year
a Non-steroidal anti-inflammatory drugs, anti -diarrheals, laxatives, and antibiotics are permitted for up to 10 consecutive days if 
taken for a condition unrelated to UC
b See Section 4.2(Exclusion Cr iteria) for exceptions to these excluded prior medications. 
c Does not include current 5-aminosalicylic acid treatment
Administration of the following medication during the stud y is not permitted and will result in 
withdrawal of the subject:
Systemic or rectal corticosteroids. 
Other medications containing 5 -ASA (eg, sulfasalazine or mesalamine/mesalazine), 
including topical administration
Immunomodulators (eg, 6-mercaptopurine, azathioprine, cy closporine, methotrexate)
Biologics (eg, anti -tumor necrosis factor agents, such as infliximab).
The following are also prohibited: nicotine patches, any products containing fish oils (fish oils 
are prohibited unless on a stable dose 4 weeks prior to the Screening Visit [Visit 1] and 
throughout stud y participation) , or an y investigational or marketed drug that may  interfere with 
the evaluation of the investigational product.
In the event of an y prohibited UC medication use during the Double -blind Maintenance Phase, 
the subject should notify  the investigator who will assess if the subject is experiencing a possible 
acute flare.
Shire CONFIDENTIAL Page 44
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Non-steroidal anti -inflammatory  drugs, anti -diarrheals, laxatives, antibiotics, and drugs that 
cause constipation are permitted for up to 10 consecutive day s if taken for a condition unrelated 
to UC.  Prophy lactic use of a stable dose of aspirin up to 325mg/day  for cardiac disease is 
permitted.  For mild, acute pain, acetaminophen is recommended.
Administration of seasonal vaccine s is permitted during the stud y;however, routine vaccinations 
should be deferred until after study  completion where possible.
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test product is MMX mesalamine/mesalazine, which will be provided in 300, 600, and 
1200mg tablet form.  Matching placebo will also be provided in tablet form.  Additional 
information is provided in the current MMX Mesalazine (Mesalamine) Investigator’s Brochure.
6.1.1 Blinding the Treatment Assignment
This study  includes double -blind treatment in the Double -blind Acute Phase and Double- blind 
Maintenance Phase.  The actual double -blind treatment given to individual subjects is 
determined b y a randomization schedule which will be automatically  assigned by  the interactive 
response technology (IRT).  Placebo, which exactly  matches the investigat ional product, will be 
used in the blister packs to provide the same number and size tablets for each of the doses within 
a weight group and maintain the blind between the low and high dose groups.
6.2
Administration of Investigational Product(s)
6.2.1 Interactive R esponse Technology for Investigational Product Management
Interactive response technology  will be used for the following investigational product tasks:
 Randomization
 Supply  management
 Inventory  management and supply  ordering
 Expiration tracking
 Returns
 Emergency  unblinding .
6.2.2 Allocation of Subjects to Treatment 
This study  includes 2 double -blind phases with low and high -dose MMX 
mesalamine/mesalazine.  The actual double- blind treatment given to individual subjects is 
determined b y a randomization schedule stratified by  weight group.  Randomization will be a 1:1 
ratio between low and high doses.
Shire CONFIDENTIAL Page 45
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subject numbers are assigned to all subjects as they consent to take part in the study .  Within 
each site (numbered uniquely  within a protocol), the subject number is assigned to subjects 
according to the sequence of presentation for study participation.  
The randomization number represents a unique number corresponding to investigational product 
allocated to the subject, once eligibility  has been determined.  
Individ ual subject doses in the Double -blind Acute Phase are automaticall y assigned b y the IRT 
based on subject weight group at the Baseline Visit (Visit 2).  I f the subject is directly  entering 
the Double -blind Maintenance Phase, individual doses are also automa tically  assigned b y the 
IRT based on subject weight group at the Baseline Visit (Visit 2).  
Individual subject open -label treatment is automatically  assigned by  the IRT and will be the high 
dose based on the subject’s weight group at Visit 3.2 (Week 8/Wit hdrawal of the Double -blind 
Acute Phase).   
Individual subject double-blind doses for subjects being re- randomized to the Double -blind 
Maintenance Phase after completion of treatment at Visit 3.2 (Week 8 of the Double -blind Acute 
Phase) or Visit 4.2 (Week 8 of the Open- label Acute Phase) are automatically  assigned b y the 
IRT based on subject weight group at the time of re- randomization.  
6.2.3 Dosing
Subjects entering the Double -blind Acute Phase or entering the Double- blind Maintenance P hase 
directly  will be r andomized to low -or high- dose MMX mesalamine/mesalazine stratified by  
their weight group at the Baseline Visit (Visit 2).  
Subjects entering the Double -blind Maintenance Phase after completing 1 or both of the Acute 
Phases will be re -randomized to low - or high - dose MMX mesalamine/mesalazine at the start of 
the Double -blind Maintenance Phase at Visit 3.2 (Week 8 of the Double- blind Acute Phase) or 
4.2 (Week 8 of the Open -label Acute Phase), as applicable, based on their weight at the time of 
re-randomization.  
Doses will be as follows:
 900 or 1800mg/day  for subjects weighing 18 to  23kg
 1200 or 2400mg/day  for subjects weighing >23 to  35kg
 1800 or 3600mg/day  for subjects weighing >35 to  50kg
 2400 or 4800mg/day  for subjects weighing >50 to  90kg.
Subjects participating in the Open -label Acute Phase will receive the high dose for their weight 
group.  The subject’s weight at Visit 3.2 (Week 8/Withdrawal of the Double -blind Acute Phase) 
will be used to determine the high dose assigned to the subject.
Investiga tional product will be administered orall y, once dail y, in accordance with the MMX 
Mesalazine (Mesalamine) Investigator’s Brochure.  No titration or dose adjustment is allowed.
Shire CONFIDENTIAL Page 46
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Dosing with investigational product will begin the day  of the Baseline Visit (V isit 2) if the 
subject’s currently  prescribed 5 -ASA treatment (if applicable) has not y et been taken that day .  If 
the subject’s currentl y prescribed 5 -ASA treatment (if applicable) has been taken the day  of the 
Baseline Visit (Visit 2), dosing with investigational product will begin the day  after the Baseline 
Visit (Visit 2).
When proceeding through study  phases, dosing with newly  prescribed investigational product 
will begin the day  of the study  visit if the subject’s currentl y prescribed investigational product 
from the current phase has not y et been taken that day .  If the subject’s currently  prescribed 
investigational treatment has been taken the day  of the study  visit, dosing with newly  prescribed 
investigational product will begin the day  after the fi rst study  visit of the new phase.
6.2.4 Unblinding the Treatment Assignment
The treatment assignment must not be broken during the stud y except in emergency situations 
where the identification of the investigational product is required for further treatment of t he 
subject.  Prior to unblinding, and if the situation allows, the investigator should first contact the 
medical monitor.  
In the event that the treatment assignment is broken, the date, the signature of the person who 
broke the code and the reason for br eaking the code are recorded in the IRT and the subject’s 
medical records.  An y code breaks that occur must be reported to the medical monitor/sponsor as 
soon as possible.  
Code break IRT access is held by the pharmacist/designated person at the site and by the medical 
monitor, or designee, for the study .  There will be a provision for unblinding to ensure adequate 
treatment of the subject in the case of an emergency.
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the investigational 
product(s) packaging. 
All investigational product is labeled with a minimum of the protocol number, medication 
identification number (open -label supplies onl y), dosage form (including product name and 
quantity  in pack), directions for use, storage conditions, expiry ), batch number and/or packaging 
reference, the statements ‘For clinical trial use only’, and/or ‘CAUTION: New Drug -Limited by  
Federal (or US) Law to Investigational Use’, and ‘Keep ou t of reach of children’, and the 
sponsor's name and address.  Any  additional labeling requirements for participating countries 
will also be included on the label.
Space is allocated on the label so that the site representative can record a unique subject 
identifier and initials (where permitted by  local laws).
Shire CONFIDENTIAL Page 47
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Additional labels may , on a case- by-case basis, be applied to the investigational product in order 
to satisfy  local or institutional requirements, but must not:
 Contradict the clinical study  label
 Obscure the clinical study label
Additional labels may  not be added without the sponsor’s prior full agreement.
If an investigator site requires a subject’s name to be included on the additional label in order for 
the subject to receive investigational produc t, the investigator site must ensure that the additional 
label is remove dor de -identified before returning investigational product to the sponsor 
nominated contractor for destruction. By  removing the label with the subject’s name, the sponsor 
will not have access to the subject’s identity  and hence confidentiality  will be preserved.
6.3.2 Packaging
Double-blind investigational product is packaged in blister pack wallets containing a 1- week 
supply  of product (tablet quantity  dependent on weight group).  Placebo, which exactly  matches 
the investigational product, will be used in the blister packs to provide the same number and size 
tablets for each of the doses within a weight group and maintain the blind between the low and 
high dose groups.
Open -label investigational product is packaged in 100cc high- densit y pol yethylene bottles in the 
following counts:
 600mg=60 tablets/bottle
 1200mg=40 tablets/bottle
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the spons or.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location.  L imited responsibility  may  be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be documented.  Investigational products are 
distributed by  the pharmacy  or nominated member of the study  team.  The pharmacist/nominated 
team member will enter the unique subject identifier and initials (where permitted by  local law) 
on the investigation al product blister pack wallets/bottles as they  are distributed.
Investigational product must be stored in accordance with labeled storage conditions.  
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range.  The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by using either an 
in-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required.  
Shire CONFIDENTIAL Page 48
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Such a device(ie,certified min/max thermometer) would require manual resetting upon each 
recording.  The sponsor must be notified immediately  upon discovery  of any  excursion from the 
established range.  Temperature excursions will require site investigation as to cause and 
remediation.  The sponsor will determine the ultimate impact of excursions on the investigational 
product and will provide supportive documentation as necessary.  Under no circumstances 
should the product be dispensed to subjects until the impact has been determined and the product 
is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry  out 
this protocol for the agreed number of subjects.  The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition.  Accurate 
records of all investigational product dispensed, used, returned, and/or destroy ed must be 
maintained as detailed further in this section.
The investigator has overall resp onsibility  for administering/dispensing investigational product.  
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator.   
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  the investigator in the applicable study  
delegation of authorit y form) will dispense the investigational produ ct only  to subjects included 
in this study  following the procedures set out in the study  protocol.  Each subject will be given 
only the investigational product carry ing his/her treatment assignment.  All dispensed medication 
will be documented in the eCRFs and/or other investigational product record.  The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects. No investigational 
product stock or returned inventory  from a Shire -sponsored study  may  be removed from the site
where originally  shipped without prior knowledge and consent by  the sponsor.  If such transfer is 
authorized by  the sponsor, all applicable local, state, and national laws must be adhered to for the 
transfer.
The sponsor or its representatives must be per mitted access to review the supplies storage and 
distribution procedures and records provided that the blind of the study  is not compromised.
At the end of the stud y, or as instructed b y the sponsor, all unused stock , subject -returned 
investigational produ ct, and empty /used investigational product packaging are to be sent to a 
nominated contractor on behalf of the sponsor.  Investigational product being returned to the 
sponsor’s designated contractors must be counted and verified b y clinical site personnel and the 
sponsor (or designated contract research organization [ CRO
]).  For unused supplies where the 
original supplied tamper -evident feature is verified as intact, the tamper -evident feature must not 
be broken and the labeled amount is to be documented in lieu of counting.  Shipment return 
forms, when used, must be signed prior to shipment from the site.  
Shire CONFIDENTIAL Page 49
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Validated electronic return systems (ie, IRT) do not require a shipment form.  Returned 
investigational product must be packed in a tamper-evident manner to ensure product integrit y.  
Contact the sponsor for authorization to return any investigational product prior to shipment.  
Shipment of all returned investigational product must comply  with local, state, and national laws.
Based on entries in the site d rug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned.  All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Compliance
Subjects must be instructed to bring their unused investigational product and empty /used 
investigational product packaging to every  visit.  Investigational product accountability  must be 
assessed at the container/packaging level for unu sed investigational product that is contained 
within the original tamper-evident sealed container (eg, bottles) or at the individual count level 
for opened containers/packaging.  The pharmacist/nominated person will record details on the 
investigational pr oduct accountability form.
If investigational product accountabilit y determines that the subject has not taken investigational 
product at the dose prescribed, the subj ect and/or caregiver will be re-educated as to the protocol 
dosing requirements.
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1, Table 2 , and Table 3 for stud y procedures.
7.1.1 Screening Period 
7.1.1.1 Screening Visit (Visit 1)
The Screening Visit (Visit 1) for this study  is a period of 3 to 21days prior to the Baseline Visit 
(Visit 2).  The Screening Visit (Visit 1) date will be considered the date of the first screening 
procedure (eg, informed consent/assent signature, during the Screening Period).  Individual 
screening procedures may be performed at an y time during the period of the Screening Visit 
(Visit 1).  All procedures must be completed within this 3 -to 21-day period before the Baseline 
Visit (Visit 2).
The Screening Visit (Visit 1) period of 3 to 21days may  be extended if the eligibility  endoscopy  
is not adequate for assigning a mucosal appearance score due to inadequate bowel preparation as 
determined b y the principal investigator or central endoscop y reader.  In this case, if endoscop y 
is to be repeated during the period of the Screening Visit (Visit 1), the Baseline Visit (Visit 2) 
may occur up to 14 day s following initial endoscopy  performed during the Screening Visit 
(Visit 1).  The repeat endoscopy  must be planned in adequate time to allow the Baseline Visit 
(Visit 2) to occur a t amaximum of 14 day s following the initial endoscopy .  
Shire CONFIDENTIAL Page 50
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Each subjectand/or caregiver will be instructed to continue completion of the electronic -diary  
(e-diary )every  night before bedtime during the period of the extended Scree ning Visit (Visit 1).
During the period of the Screening Visit (Visit 1), the subject must re main on their curre nt 
5-ASA medication for UC (if applicable) at a stable dose until the Baseline Visit (Visit 2), at 
which time current treatment must be discontinued.  If being screened for entry  into the 
Double
-blind Acute Phase, the current 5- ASA dose must not be higher than the MMX 
mesalamine/mesalazine low dose for the subject’s weight group.  
Subjects should not use any  other concomitant medication for their UC during the period of the 
Screening Visit (Visit 1 ).  Weight will be measured to ensure that this parameter is within 
protocol -defined limits during the period of the Screening Visi t (Visit 1).  Weight will be 
re-assessed at the Baseline Visit (Visit 2) for eligible subjects to determine randomization 
stratification. 
Collection of stool sample s for all assessments must occur before administration of any  bowel 
preparations for endoscopy if samples are collected on the same day  as bowel preparation 
administration.  Stool samples collected for culture may  be processed by  local laboratories; 
howeve r, results from the central laboratory  anal ysis will prevail and will be entered into the 
eCRF.
Subjects without a confirmed diagnosis of UC: 
Endoscopy  (flexible sigmoidoscopy  or colonoscopy ), including biopsies taken for confirmatory  
histology , must be p erformed during the period of the Screening Visit (Visit 1).  The biopsies 
taken for confirmation of UC diagnosis will be sent to the site’s local laboratory .  Confirmatory  
results to verify  the subject’s UC diagnosis must be received prior to the Baseline Visit (Visit 2) 
for randomization.
Subjects with a historical diagnosis of UC: 
Subjects who have been diagnosed with UC (endoscopic and histologic reports of diagnosis are 
available) prior to the Screening Visit (Visit 1) will be considered to have a his torical diagnosis 
of UC.  For subjects who have had endoscop y within the 21 days prior to screening ,if the 
endoscop y is consistent with UC ,the subject may proceed to the Screening Visit (Visit 1) with a 
historical diagnosis of UC.  The subject can be ran domized once the endoscopy  confirms the 
diagnosis of UC. The histologic confirmation of UC can be available after the Baseline Visit 
(Visit 2).  (See next paragraph below for additional details.)  
Subjects who enter the Double -blind Acute Phase:
If a stan dard of care endoscopy  (flexible sigmoidoscopy  or colonoscopy , including biops y) 
hasbeen performed within 21days prior to the Screening Visit (Visit 1) and appropriate video 
orphotographs of the procedure were obtained, these assessments may  be used in lieu of 
performing an endoscop y during the period of the Screening Visit (Visit 1) or at the 
Baseline Visit (Visit 2).  The video or photographs of this endoscopy  must be de -identified 
andsubmitted to the study ’s central reader for confirmation of study  eligibility  after informed 
conse nt for the stud y is obtained.  
Shire CONFIDENTIAL Page 51
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Thelocal laboratory histology report confirming thediagnosis of UC may  be pending upon entry  
into the study  at the Screeni ng Visit (Visit 1); however, the confirmatory  histology  report must 
beavailable before randomization at the Baseline Visit (Visit 2). All other protocol -required 
assessments (including all laboratory  assessments, ie, blood, urine and stool collection) must be 
performed for the Screening Visit (Visit 1) even if recent resul ts are available.
For subject’s whose historical diagnosis of UC was made more than 21days prior to the 
Screening Visit (Visit 1), then a study  specific endoscopy  must be performed during the period 
of the Screening Visit (Visit 1) or at the Baseline Visi t (Visit 2).  Biopsies are not required for 
this endoscopy  provided that a histology  report with results that are compatible with UC is 
present in the subject’s source documents. The confirmatory  histology  may  have been at any  
time in the subject’s histor y.If histologic confirmation of the previous UC diagnosis is not 
available in source documents, the entry  endoscopy  and confirmatory  histology  must be 
performed during the period of the Screening Visit (Visit 1) as for those subjects without a 
confirmed diagnosis of UC.
Subjects who enter the Double -blind Maintenance Phase directly:
All subjects must have a study  endoscop y (flexible sigmoidoscop y or colonoscopy) performed 
during the period of the Screening Visit (Visit 1) or at the Baseline Visit (Visit 2 ).   Biopsies are 
not required for this endoscopy  provided that a histology  report with results that are compatible 
with UC is present in the subject’s source documents. The confirmatory  histology  may  have 
been at an y time in the subject’s history. If histologic confirmation of the previous UC diagnosis 
is not available in source documents, the entry  endoscopy  and confirmatory histology  must be 
performed during the period of the Screening Visit (Visit 1) as for those subjects without a 
confirmed diagnosis of UC.
All subjects: 
Endoscopic video or photographs will be collected and sent to the study ’s central 
endoscopy  
reader for evaluation of mucosal appearance.  
Mucosal appearance (endoscopy  score) entry  criterion should be assessed based on the central 
reader score, if available.  Only  in the event that the central reader score is not available at the 
time of the Baseline Visit (Visit 2) should the local reading be used.  However, the central 
reader’s score will be used for the calculation of the full UC- DAI score.
Please see a description of criteria used for endoscopic scoring in Appendix 2 .
Stool collection (for eligibility  assessments,  
) may  occur at any  time during the period of the Screening Visit (Visit 1), 
provided that written informed consent/assent has been collected before this procedure .  If a 
standard of care stool sample has been collected within 24 hours prior to the Screening Visit 
(Visit 1), this sample may be used for screening assessments and evaluations provided that 
written informed consent/assent has been collected before the stool is sent for laboratory  
analysis.Stool samples collected for culture may  be processed by  local laboratories;  however, 
results from the central l aboratory  analy sis will prevail and will be entered into the eCRF.   

Shire CONFIDENTIAL Page 52
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subjects with positive stool cultures for an y enteric pathogen (see Section 4.2) will not be 
eligible for the study .
Results for eligibility  assessments must be available and evaluated pri or to the end of the period 
of the Screening Visit (Visit 1) and prior to randomizati on at the Baseline Visit (Visit 2).
Instructions relative to the use of the e
-diary  for UC -DAI s ymptoms (rectal bleeding andstool 
frequency ), the DUCS, and Overall Curren t Health entry  will be reviewed with the subject and/or 
caregiver, and a training diary  entry  must be completed prior to live data entry .  Starting from the 
first evening of the period of the Screening Visit (Visit 1), each subject and/or caregiver will be
instructed to complete the e -diary  every  night before bedtime during the period of the Screening 
Visit (Visit 1). It is recommended that s ite staff telephone the subject or the subject’s caregiver
approximately  4to 7days prior toeach visit to remind th em to answer the questions in the 
e-diary  every  night, even if they  have no symptoms. I t is of parti cular importance to remind the 
subject at least 3 days prior to the Baseline Visit (Visit 2) to complete the questions in the e- diary  
as this information is required to assess the eligibility  of the subject. 
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized or administered 
investigational product(s).  Subjects who do not meet all the eligibility  criteria for either the 
Double-blind Acute Phase or the Double- blind Maintenance Phase or who do not have s ymptom 
score data available (stool frequency andrectal bleeding), (see Section 7.2.1.1 fordetails) , will 
be considered screen failures .  Subjects may  be rescreened after consultation with the medical 
monitor.
7.1.1.2 Recommended 
Telephone Call (Day ⎼ 7to ⎼4)
Approximately  4 to 7days prior to the Baseline Visit (Visit 2) , it is recommended that site staff 
telephone the subject or the subject’s caregiver to remind them to enter UC- DAI s ymptoms 
(rectal bleeding andstool frequency ) into the e- diary every  night, even if the subject has no 
symptoms .
7.1.1.3 Baseline Visit (Visit 2)
The B aseline visit will take pla ce 3 to 21 days after the first day  of the Screening Visit (Visit 1) 
to allow blood and stool tests to be anal yzed, and for collection of e -diary  data.  An extension to 
this 3 -to 21-day period is allowed only  in the case where a repeat endoscopy  will be performed 
during the period of the Screening Visit (Visit 1) (see Section
 7.1.1.1 ).  
The 3-day visit window which is applicable to other study  visits is not applicable to this visit.  
The partial UC -DAI score will be calculated by  the site, and the mucos al appearance (endoscopy  
score) will be evaluated separately to determine eligibility  for either the Double -blind Acute 
Phase or the Double -blind Maintenance Phase.  The following criteria will determine the study  
phase a subject can 
be eligible to enter:
 Subjects with partial UC -DAI ≥2 (with a combined rectal bleeding andstool frequency  
score ≥1 andPGA=1 or 2) and with mucos al appearance (endoscop y score)=2 or 3 will be
eligible to enter the Double -blind Acute Phase.
Shire CONFIDENTIAL Page 53
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
 Subjects with partial UC -DAI ≤1 (with rectal bleeding=0 andstool frequency  ≤1 and
PGA=0) andwith mucosa l appearance (endoscopy  score)=0 or 1 will be eligible to enter 
the Double -blind Maintenance Phase. 
Subjects with partial UC -DAI score between 1 and 2 will not be eligible to enter the Do uble-
blind Acute Phase or the Double
-blind Maintenance Phase.
Subjects who do not meet all the eligibility  criteria for either the Double -blind Acute Phase or 
the Double -blind Maintenance Phase will be considered screen failures. Subjects may  be 
rescreene d after consultation with the medical monitor.
A minimum of 1 score each for stool frequency  and rectal bleeding must be available in order to 
randomize subjects into either the Double -blind Acute Phase or the Double -blind Maintenance 
Phase (see Section 7.2.1.1 for details). Subjects with no sy mptom score data available will be 
considered screen failures as these s ymptom score data are used to calculate the partial U C
-DAI 
score needed for enrollment.
Subjects with a historical diagnosis of UC:  
Endoscopy  (flexible sigmoidoscopy  or colonoscopy ) must be performed at the Baseline Visit 
(Visit 2) if not performed at the Scre ening Visit (Visit 1) or within 21 days prior to the Screening 
Visit (Visit 1) ( 21days prior applicable onl y to subjects entering into the Double -blind Acute 
Phase directl y).  Endoscopic video or photographs will be collected and sent to the study’s 
central endoscopy reader for evaluation of mucosal appearance.  
Please see a description of criteria used for endoscopic scoring in Appendix 2 .
If the results of blood andstool tests or partial UC -DAI score show that the subject is not eligible 
for the stud y, he/she will not continue in the study  and will be considered a screen failure.  No 
additional data will be captured for these subjects.
Eligible subjects will be randomized to low -or high
-dose MMX mesalamine/mesalazine 
stratified by  their weight group at the Baseline Visit (Visit 2).  I f a subject’s weight changes 
during a stud y phase, their dose will not change.  
Weight groups have the sa me absolute low and high doses for both the Double -blind Acute 
Phase and the Double -blind Maintenance Phase (see Section 6.2.3).  
Double
-blind investigational product will be dispensed to eligible subjects per the procedures 
detailed in Section 6.
Subjects and/or caregivers will be instructed to collect UC- DAI s ymptoms (rectal bleeding and
stool frequency ) via e -diary  once a day  before bedtime for 5 days prior to each study  visit in the 
Double- blind Acute Phase and/or Double -blind Maintenance Phase as applicable.  The average 
stool frequency  and rectal bleeding scores will be calculated and be made available to the 
investigator through a report from the e -diary  provider.  The average stool frequency  and rectal 
bleeding scores will be added to the PGA score determined b y the investigator to calculate the 
partial UC -DAI.  Please see a description of the PGA in Section 7.2.1.1 and the UC -DAI in 
Sections 7.2.1.1 and 7.2.1.2 .
Shire CONFIDENTIAL Page 54
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subjects and/or caregivers will be instruct ed to complete the DUCS and the Overall Current 
Health e -diary  once a day  before bedtime for 5 day s prior to each study  visit in the Double -blind 
Acute Phase or Double -blind Maintenance Phase as applicable.  
The IMPACT III questionnaire will be completed by children aged 8 -17 years via paper at the 
Baseline Visit (Visit 2).  Please see a description of the IMPACT III questionnaire in 
Section 7.2.4.1.
The PUCAI score will be calculated b y a physician at the site, where applicable.  Please see a 
description of the PUCAI in Section 7.2.4.1.
See Table 
1andTable 3 for a listing of all Baseline Visit (Visit 2) procedures.
7.1.1.4 Subject Visit Schedule Summary Post- baseline
Following the Baseline Visit (Visit 2), subjects will proceed through the study  in 1 of 3 way s.
1. Double- blind Acute Phase → Open -label Acute Phase → Double-blind Maintenance 
Phase.
Visits completed post- Baseline Visit (Visit 2) are as follows: Visit 3, Visit 3.1, Visit 3.2, Visit 4, 
Visit 4.1, Visit 4.2, Visit 5, Visit 5.1, Visit 5.2 ,and Visit 6.
Note that Visit 3.1 and/or Visit 3.2 may  not be completed in the case that a subject enters into the 
Open -label Acute Phase without completing the Double -blind Acute Phase.  See Section 7.1.3
for the criteria for subject eligibility to enter the Open -label Ac ute Phase.
2. Double- blind Acute Phase → Double- blind Maintenance Phase.
Visits completed post- Baseline Visit (Visit 2) are as follows: Visit 3, Visit 3.1, Visit 3.2, Visit 5, 
Visit 5.1, Visit 5.2, and Visit 6.
3. Double- blind Maintenance Phase onl y.
Visits completed post- Baseline Visit (Visit 2) are as follows: Visit 5, Visit 5.1, Visit 5.2, and 
Visit 6.
7.1.2 Double -blind Acute Phase
7.1.2.1 Recommended Telephone Call ( Day⎼7 to ⎼4)
Approximately  4 to 7days prior to the Baseline Visit (Visit 2) and prior to each subsequent visit 
(Visit s 3, 3.1, and 3.2) , it is recommended that site staff telephone the subject or the subject’s 
caregiver to remind them to enter UC -DAI symptoms (rectal bleeding andstool frequency ) into 
the e -diary  every  night, even if the subject hasno sy mptoms .
7.1.2.2 Double -blind Acute Phase Weeks 2 and 4 (Visits 3 and 3.1, respectively) 
Subjects and/or caregivers will collect UC- DAI s ymptoms (rectal bleeding andstool frequency ) 
via e -diary  and will complete the DUCS and the Overall Current Health e -diary  once a day  
before bedtime for 5 days prior to each study visit in the Double -blind Acute Phase.  
Shire CONFIDENTIAL Page 55
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
ThePGA score will be determined by  the investigator.  Please see a description of the PGA in 
Section 7.2.1.1.
The Global Change in Health questionnaire will be completed via paper at Visits 3 and 3.1.   
Please see a description of the Global Change in Health questio
nnaire in Section 7.2.4.1.
See Table 
1for a listing of all Visit 3 and Visit 3.1 procedures.
7.1.2.3 Double -blind Acute Phase Week 8/Withdrawal (Visit 3.2)
The Double -blind Acute Phase Withdrawal Vi sit may  occur at any  time the subject discontinues 
participation in the Double -blind Acute Phase, or at completion of the study at Week 8 of the 
Double-blind Acute Phase.  No additional Baseline Visit is required for subjects continuing into 
the Open -label Acute Phase or the Double -blind Maintenance Phase from this visit.
Subjects with a clinical r esponse ie, partial UC -DAI ≤1 ( with rectal bleeding=0 andstool 
frequency ≤1 andPGA=0 ) will be weighed an
d re-randomized into the Double -blind 
Maintenance Phase for treatment with low -or high -dose MMX mesalamine/mesalazine stratified 
by weight group based on current weight.  Please see Section 6.2.3 for weight- stratified 
randomization groups.  Subjects without a clinical response may continue into the Open- label 
Acute Phase and receive MMX mesalamine/mesalazine at the high dose for their weight group, 
based on their weight at Visit 3.2 (Week 8/Withdrawal of the Double -blind Acute Phase).
Collection of stool samples for all assessments must occur before administration of an y bowel 
preparations for endoscopy if samples are collected on the same day  as bowel preparation 
administration.
Endoscopy  (flexible sigmoidoscopy  or colonoscopy ) should be performed at Visit 3.2 for 
subjects who are not entering into the Open -label Acute Phase.  If performed, endoscopic video 
or photographs will be collected and sent to the study ’s central endoscopy  reader for evaluation 
of mucosal healing .  Please see a description of criteria used for endoscopic scoring in Appendix 
2.  If endoscop y is not performed at Visit 3.2 and the subject is otherwise eligible, the subject 
may remai n in the study .
Subjects and/or caregivers will have collected UC
-DAI s ymptoms (rectal bleeding andstool 
frequency ) via e -diary  once a day  before bedtime for 5 day s prior to each study  visit in the 
Double- blind Acute Phase.  The average stool frequency  and rectal bleeding scores will be 
calculated and be made available to the investigator through a report from the e -diary  provider.  
The average stool frequency  and rectal bleeding scores will be added to the PGA score 
determined b y the investigator to calcu late the partial UC -DAI.  Please see a description of the 
PGA in Section 7.2.1.1 and the UC -DAI in Sections 7.2.1.1 and 7.2.1.2.
The IMPACT III (for children aged 8 -17 years) and Global Change in Health questionnaires will 
be completed via paper at Visit 3 .2.  Please see a description IMPACT III and Global Change in 
Health questionnaires in Section 7.2.4.1.
Shire CONFIDENTIAL Page 56
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The PUCAI score will be calculated b y a physician at the site, where applicable.  Please see a 
description of the PUCAI in Section 7.2.4.1.
A pharmacoki netic sample will be taken with the biochemistry  and hematology  sample from 
subjects at sites qualified for and participating in the pharmacokinetic sampling.  Please see a 
description of the pharmacokinetic sampling in Section 7.2.3.
See Table 
1for a listing of all Visit 3.2 procedures.
7.1.3 Open -label Acute Phase
Subjects may  enter the Open -label Acute Phase after completion of the Double -blind Acute 
Phase if they  do not meet the requirements for entry  into the Double -blind Maintenance P hase ie, 
they do not a chieve a clinical response defined as a p artial UC -DAI ≤1 ( with rectal bleeding=0
andstool frequency  ≤1 andPGA=0 ).  This phase is intended to allow those subjects without 
clinical response in the Double
-blind Acute Phase an additional 8 weeks to achieve clinical 
response at the high dose for their weight group.  The subject’s weight at Visit 3.2 
(Week 8/Withdrawal of the Double -blind Acute Phase) will be used to determine the high dose 
assigned to the subject in the Open -label Acute Phase.
Subjects are al so eligible for the Open -label Acute Phase provided they  have participated in the 
Double-blind Acute Phase for a minimum of 2 weeks and, in the investigator’s opinion, have not 
benefited from treatment in the Double- blind Acute Phase.  In addition, they  should not have 
experienced a possibl y or probably related severe adverse event ( AE)or a serious AE ( SAE ).  
Due to the delay  in onset of action of 5- ASA preparations, investigators should make 
subjects/caregivers aware that they  may  not benefit from the inv estigational product within the 
first 2 weeks.  Subjects who withdraw before Visit 3 will not be eligible for the Open -label Acute 
Phase.  
7.1.3.1 Recommended Telephone Call (Days ⎼7to ⎼4)
Approximately  4to 7days prior to 
Visit 4and prior to each subsequent visit (Visits 4.1 and 4.2) ,
it is recommended that site staff telephone the subject or the subject’s caregiver to remind them 
to enter UC -DAI symptoms (rectal bleeding andstool frequency ) into the e -diary  every  night, 
even if the subject hasno sy mptoms .
7.1.3.2 Open -label Acute Phase Weeks 2 and 4 (Visits 4 and 4.1, respectively) 
Subjects and/or caregivers will collect UC- DAI s ymptoms (rectal bleeding andstool frequency ) 
via e -diary and will complete the DUCS and the Overall Current Health e -diary  once a day  
before bedtime for 5 days prior to each stud y visit in the Open- label Acute Phase.  
See Table 2 for a listing of all Visit 4 and 4.1 procedures.
7.1.3.3 Open -label Acute Phase Week 8/ Withdrawal (Visit 4.2)
The Open -label Acute Phase Withdrawal Visit may  occur at any  time the subject discontinues 
participation in the Open -label Acute Phase, or at completion of the study  at Week 8 of the 
Open -label Acute Phase.  No additional Baseline Vi sit is required for subjects continuing into the 
Double- blind Maintenance Phase from this visit.
Shire CONFIDENTIAL Page 57
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subjects with a clinical response, ie, partial UC -DAI ≤1 ( with rectal bleeding=0 andstool 
frequency ≤1 andPGA=0 ) will be weighed an
d re-randomized into the Double -blind 
Maintenance Phase of the study  for treatment with low -or high -dose MMX 
mesalamine/mesalazine stratified by  the weight gro up based on current weight.  Please see 
Section 6.2.3 for weight -stratified randomization groups.  
Subjects without a clinical response after completion of the Open
-label Acute Phase will be 
withdrawn from the study at Visit 4.2.  The Follow- up Visit 6 mu st be conducted.
Collection of stool samples for all assessments must occur before administration of an y bowel 
preparations for endoscopy if samples are collected on the same day  as bowel preparation 
administration.
Endoscopy  (flexible sigmoidoscopy  or col onoscopy ) should be performed at Visit 4.2.  I f 
performed, endoscopic video or photographs will be collected and sent to the study ’s central 
endoscop y reader for evaluation of mucosal healing .  Please see a description of criteria used for 
endoscopic scori ng in Appendix 2 .  If endoscopy  is not performed and the subject is otherwise 
eligible at Visit 4.2, the subject may  remain in the study .
Subjects and/or caregivers will have collected UC- DAI s ymptoms (rectal bleeding andstool 
frequency ) via e -diary  once a day  before bedtime for 5 day s prior to each study  visit in the Open -
label Acute Phase.  The average stool frequency  and rectal bleeding scores will be calculated and 
be made available to the investigator through a report from the e -diary  provider.  The a verage 
stool frequency  and rectal bleeding scores will be added to the PGA score determined by  the 
investigator to calculate the partial UC- DAI.  Please see a description of the PGA in Section 
7.2.1.1 and the UC -DAI in Sections 7.2.1.1 and 7.2.1.2.
The PUC AI score will be calculated b y a physician at the site, where applicable.  Please see a 
description of the PUCAI in Section 7.2.4.1.
A pharmacokinetic sample will be taken with the biochemistry  and hematology  sample from 
subjects at sites qualified for and participating in the pharmacokinetic sampling.  Please see a 
description of the pharmacokinetic sampling in Section 7.2.3.
See Table 2 for a listing of all Visit 4.2 procedures.
7.1.4 Double -blind Maintenance Phase
7.1.4.1 Recommended 
Telephone Call ( Days ⎼7 to ⎼4)
Approximately  4 to 7days prior to the Baseline Visit (Visit 2) and prior to each subsequent visit 
(Visits5, 5.1, and 5.2) , it is recommended that site staff telephone the subject or the subject’s 
caregiver to remind them to enter UC -DAI symptom s (rectal bleeding andstool frequency ) into 
the e -diary  every  night, even if the subject hasno sy mptoms .
7.1.4.2 Double -blind Maintenance Phase Weeks 2 -4 (Visit 5)
Subjects and/or caregivers will return to the study site once between 2 -4 weeks after 
randomizatio n into the Double -blind Maintenance Phase.  
Shire CONFIDENTIAL Page 58
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Thepurpose ofthisvisit is to dispense additional investigational product.  Unused investigational 
product and empt y/used investigational product packaging will be collected.  
The subject does not need to be p resent for this visit; it is sufficient for the caregiver onl y to 
return to the study site for investigational product dispensation and collection procedures.
No study  procedures other than investigational production dispensation and collection are 
perform ed at Visit 5; however, if information is offered by  the subject or caregiver that indicates 
an AE has occurred, the relevant information will be collected and followed up as described in 
Section 8.
See Table 
3for a listing of all Visit 5 procedures.
7.1.4.3 Doub le-blind Maintenance Phase Week 13 (Visit 5.1)
Subjects and/or caregivers will collect UC- DAI s ymptoms (rectal bleeding andstool frequency ) 
via e -diary  and will complete the DUCS and the Overall Current Health e -diary  once a day  
before bedtime for 5 days prior to each study visit in the Double -blind Maintenance Phase except 
for Visit 5, which includes collection and dispensation of investigational product only.  
See Table 3 for a listing of all Visit 5.1 procedures.
7.1.4.4 Double -blind Maintenance Phase Week 26/ Withdrawal (Visit 5.2)
The Double -blind Maintenance Phase Withdrawal Visit may  occur at an y time the subject 
discontinues participation in the Double- blind Maintenance Phase, or at completion of the study  
at Week 26 of the Double- blind Maintenance Phase.
Collection of stool samples for all assessments must occur before administration of an y bowel 
preparations for endoscopy if samples are collected on the same day  as bowel preparation 
administration.
Endoscopy  (flexible sigmoidoscopy  or colonoscopy ) should be performed at Visit 5.2 where 
possible.  I f performed, endoscopic videos or photographs will be collected and sent to the 
study ’s central endoscopy  reader for evaluation of mucosal 
healing .  Please see a description of 
criteria used for endoscopic scoring in Appendix 2 .  
Subjects and/or caregivers will have collected UC- DAI s ymptoms (rectal bleeding andstool 
frequency ) via e -diary  once a day  before bedtime for 5 day s prior to each study  visit in the 
Double- blind Maintenance Phase except for Visit 5, whic h includes collection and dispensation 
of investigational product only .  The average stool frequency  and rectal bleeding scores will be 
calculated and made available to the investigator through a report from the e -diary  provider.  The 
average stool frequen cy and rectal bleeding scores will be added to the PGA score determined by  
the investigator to calculate the partial UC -DAI.  Please see a description of the PGA in Section 
7.2.1.1 and the UC -DAI in Sections 7.2.1.1 and 7.2.1.2.
Shire CONFIDENTIAL Page 59
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The IMPACT III (for childre n aged 8 -17 years) and Global Change in Health questionnaires will 
be completed via paper at Visit 5.2.  Please see a description IMPACT III and Global Change in 
Health questionnaires in Section 7.2.4.1.
The PUCAI score will be calculated b y a physician at the site, where applicable.  Please see a 
description of the PUCAI in Section 7.2.4.1.
A pharmacokinetic sample will be taken with the biochemistry  and hematology  sample from 
subjects at sites qualified for and participating in the pharmacokinetic samplin g.  Please see a 
description of the pharmacokinetic sampling in Section 7.2.3.
See Table 
3for a listing of all Visit 5.2 procedures.
7.1.5 Follow -up Period (Visit 6)
The follow -up period for this protocol is 7 day s following last dose of investigational product.  
All subjects, whether they have completed the study  or withdrawn earl y, must have a follow -up 
contact.
At the end of this period there will be a visit or telephone call initiated by  the site staff to query  
for SAEs, AEs, and concomitant treatments.  All AEs and SAEs that are not resolved at the time 
of this contact will be followed to closure (see Section 8).
7.1.6
Additional Care of Subjects After the Study
No additional care is planned after a subject’s participation in this study  unless required b y local 
laws, ethics committees or competent authorities. The Principal Investigator at each site will be 
responsible for oversight of his or her stud y participant who continues on MMX 
mesalamine/mesalazine after study  completion as a part of the aftercare program.
7.2 Study Evaluations and Procedures
7.2.1 Efficacy
The primary  efficacy  assessment of the Double- blind Acute Phase is the proportion of subjects 
with a clinical response (defined as partial UC- DAI ≤1 with rectal bleeding=0 andstool 
frequency  ≤1 andPGA=0) at Week 8.  The primary  efficacy  assessment of the Double -blind 
Maintenance Phase is the proportion of subjects with a clinical response at Week 26.  
A secondary  efficacy  assessment of the Double
-blind Acute Phase is the proportion of subjects 
with a clinical an d endoscopic response at Week 8 defined as full UC- DAI ≤2 with rectal 
bleeding=0 andstool frequency  ≤1andPGA=0, andwith mucosal healing (endoscop y score ≤1) 
based on central reading.  I n addition, there must be at least a 1
-point reduction in endoscopy
score from baseline.  A secondary  efficacy  assessment of the Double -blind Maintenance Phase is 
the proportion of subjects with a clinical and endoscopic response at Week 26.
Shire CONFIDENTIAL Page 61
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Did y ou have blood in y our poop? 
 I didn’t see an y blood in my  poop
 I saw streaks of blood (a small amount) in my  poop
 I saw some blood (more than a small amount) in my poop
 I saw mostly  blood (a lot) in my  poop.
Questions and responses for caregivers of children aged 5 -10 years:
Based on what you observed, how man y more times did y our child have a bowel movement than 
they normally  do since they  went to bed last night?
 They  didn’t have more bowel movements than they  normal ly do
 They  had 1 or 2 more bowel movements than normal
 They  had 3 or 4 more bowel movements than normal 
 They  had 5 or more bowel movements than normal.
Based on what you observed, did your child have blood in their stool? 
 I didn’t see an y blood in my  child’s stool
 I saw streaks of blood (a small amount) in my  child’s stool
 I saw some blood (more than a small amount) in my child’s stool
 I saw mostly  blood (a lot) in my  child’s stool.
For determination of the partial UC- DAI, the average of the s ymptom score s of the last available 
3days within the 5 -day period immediately  prior to the study  visit will be used.  No sy mptom 
data older than 5 day s prior to the study  visit will be used.  Data collected on day s when bowel 
preparations have been administered or wh en endoscopy  has been performed will be excluded. 
Approximately  4 to 7days prior to the Baseline Visit (Visit 2) and prior to each subsequent visit, 
it is recommended that site staff telephone the subject or the subject’s caregiver to remind them 
to ente r UC -DAI symptoms (rectal bleeding andstool frequency ) into the e -diary every  night, 
even if the subject has no sy mptoms.  
A missed day ’s data may  be entered until 12:00 hours the 
following day .
A minimum of 1 score each for stool frequency and rectal bl eeding must be available in order to 
randomize subjects into either the Double -blind Acute Phase or the Double -blind Maintenance 
Phase. If no data are available, the average value will be considered missing and the subject will 
be considered a screen failu re.
Shire CONFIDENTIAL Page 62
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Calculations of average s tool frequency and rectal bleeding scores will proceed as follows:
If symptom scores from the last 3 day s are available, average =(x1+x2+x3)/3; the average 
value should be rounded up to 1 decimal place :
For example: (0+1+0)/3 = 0.3333; value = 0.3; (1+0+1)/3=0.666666 ; value =0.7; 
(2+2+2)/3=2.0
If symptom scores from the last 2 day s are available, average = (x1+x2)/2; the average value 
should be rounded up to 1 decimal place .
Ifsymptom scores from only 1 day  areavailable , avera ge =(x1/1) =x1.
The PGA will be performed at all visits where the partial UC- DAI score is calculated by  the 
study  site, and is scored on a scale from 0- 3, where 0=no active disease, 1=mild disease, 
2=moderate disease, and 3=severe disease.  The PGA shoul d be performed by  the same 
investigator at all visits, if possible, for consistency in evaluation.
Scoring of the PGA b y the investigator should take into account the following parameters:
 Rectal bleeding
 Stool frequency  and consistency
 Night -time bowel movements
 Abdominal pain
 Impact to daily  activities
 Physical findings
 Endoscopic findings (if endoscopy  is performed).
The PGA is to be recorded in source documentation and added to the average stool frequency  
and average rectal bleeding scores to calculate the partial UC -DAI score. Sites should not 
perform rounding of partial UC
-DAI scores. The average stool frequency  and rectal bleeding 
scores will be calculated and available to the investigator through a rep ort from the e -diary  
provider.
7.2.1.2 Modified Full UC -DAI Score
The full UC -DAI is widely  used to assess treatment efficacy  in subjects with mild to moderate 
UC ( Schroeder et al. 1987; Sutherland et al. 1987 ).  Itconsists of 4 individual parameters: stool 
frequency , rectal bleeding, endoscopy  score (mucosal appearance), and PGA.  For the purpose of 
this study , the standard UC -DAI scale has been modified so that an endoscopy score of mild 
disease does not include f riability ; instead, friability  will be scored as 2: moderate disease.  
Please see a description of stool frequency, rectal bleeding and PGA in Section 7.2.1.1.  
Shire CONFIDENTIAL Page 63
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
All 4 parameters will be assessed individually  on a scale from 0- 3; the maximum total modifie d 
full UC -DAI score is 12.0 .  The modified full UC -DAI score will be calculated at Baseline (Visit 
2), Week 8 of the Double -blind Acute Phase (Withdrawal) for subjects not entering into the 
Open -label Acute Phase, Week 8 of the Open -label Acute Phase (Withdrawal) for subjects who 
have not had endoscop y at the end of the Double -blind Acute Phase, and Week 26 of the Double -
blind Maintenance Phase (Withdrawal) visits.  The total score will be calculated by  summing the 
individual scores for the 4 parameters (en doscopy score will be based on the central reader’s 
score).  The site is not required to calculate the full UC- DAI; this will be calculated centrally  
using e -diary  and eCRF data.
For determination of the modified full UC- DAI, the average of the s ymptom sco res of the last 
available 3 days within the 5 -day period immediately  prior to study  visits where endoscopic data 
are available, will be used.  No sy mptom data older than 5 day s prior to the study  visit will be 
used.  Data collected on days when bowel prepa rations have been administered or when 
endoscop y has been performed will be excluded. 
An endoscop y must be performed and mucosal appearance scored within 21days prior to the 
Screening Visit (Visit 1), during the Screening period or at the Baseline Visit (Visit 2) depending 
on the subject’s UC history  and phase of the study into which they  are entering.  All efforts 
should be made to perform endoscop y at Week 8 of the Double -blind Acute Phase (or Week 8 of 
the Open -label Acute Phase, as app licable), Week 2 6 of the Double -blind Maintenance Phase, or 
the subject’s withdrawal if different from these visits. 
During this stud y, an attempt will be made to collect endoscop y data in approximately  30% of 
subjects at the end of the Acute Phase (combined Double- blind and Open -label) and 
approximately  30% at the end of the Double -blind Maintenance Phase.  In addition, data from 
endoscopies performed as a part of routine clinical care during a subject’s participation in the 
study  will be collected.
Endoscopies will be c entrally  read and scored for this study , and endoscopic video or 
photographs must be provided to the central reader for each endoscopy  performed.  Video 
images are preferred; however, photographic images will be accepted when video images are not 
of suffic ient qualit y, as determined b y the central reader during individual site image evaluation 
prior to enrollment at the site.  Further details of requirements for video and photographic images 
will be provided to study sites under separate cover by  the centra l reader.  All endoscopies 
should be performed b y the same investigator/endoscopist, if possible, to ensure consistency in 
endoscop y.
Please see Appendix 2 for the modified full UC -DAI.
7.2.2 Safety
The name and address of each third part y vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigator’s and sponsor’s files.
Shire CONFIDENTIAL Page 64
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
7.2.2.1 Medical and Medication History
At screening, the subject’s medical history  (including UC history ) and concomitant medications 
will be reviewed.  Investigator site s taff will conduct this review via interview with the subject 
and/or caregiver to determine eligibility .  Any new medical events or changes in intensit y from 
the Screening Visit (Visit 1) noted during the study should be evaluated for report as an AE (see 
Section 8).  New medications or changes to existing medications must be added or updated as 
appropriate.
7.2.2.2 Physical Examination 
Abnormalities identified at the Screening Visit (Visit 1) will be documented in the subject’s 
source documents. Changes after the Screening Visit (Visit 1) will be captured as AEs, as 
deemed 
appropriate by  the investigator.
7.2.2.3 Height and Weight
Height will be assessed at the Screening Visit (Visit 1) and at the final visit of each phase.  
Weight will be assessed at the Screening Visit (Visit 1), the Baseline Visit (Visit 2) and at the 
final visit of each phase.  
The collection of height and weight data should be precise. A calibrated stadiometer must be 
used for all height measurements. Height should be measured in stocking feet (witho ut shoes) 
with the subject standing on a flat surface and with chin parallel to the floor. The bod y should be 
straight but not rigid. The subject’s height should be recorded to the nearest 0.5 inch or 1 cm. 
The same calibrated scale must be used for all w eight measurements.  Weight should be 
measured in stocking feet (without shoes) and recorded to the nearest 0.2 kg. 
7.2.2.4 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the prev ious visit (eg, “Have y ou had any  health problems since y our last visit?”).  
Adverse events are collected from the time informed consent is signed.  (Please refer to 
Section 8, Adverse and Serious Adverse Events Assessment.)
In addition, any  symptoms/condi
tions reported during assessments or collected via structured 
data collection will be evaluated b y the investigator at each study visit to determine whether 
these are AEs.
7.2.2.5 Vital Signs
Vital signs include blood pressure and pulse.  Blood pressure should be determined by  cuff 
(using the same method, the same arm, and in the same position throughout the study ).  An y 
clinically  significant deviations from the Baseline Visit (Visit 2) vital signs which are deemed 
clinically  significant in the opinion of the inve stigator are to be recorded as an AE.
Measurements of vital signs (blood pressure and pulse) will be performed at all study  visits.  
Blood pressure and pulse will be determined in the sitting position (after 5 minutes).
Shire CONFIDENTIAL Page 65
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
7.2.2.6 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures.  
Reference ranges are to be supplied by  the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of-range patholog ical changes.  The investigator 
should assess out -
of-range clinical laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant.  Abnormal clinical laboratory  
values, which are unexpec ted or not explained by  the subject’s clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, 
explained, or resolved.
The following routine clinical laboratory  assessments will be performe d (see Section 8.1.5 for 
additional clinical laboratory  assessments that may be performed in the case of elevated liver 
enzy mes): 
Biochemistry (approximately 5mL sample)
Alanine aminotransferase Direct bilirubin 
Albumin Gamma -glutam yl transferase
Alkaline phosphatase Glucose random, serum
Aspartate aminotransferase Lactate deh ydrogenase
Bilirubin, total Magnesium
Bicarbonate Phosphate
Calcium Potassium
Chloride Sodium
Cholesterol, total Total protein
Creatinine, enzymatic Trigl ycerides 
Creati ne kinase Urea (blood urea nitrogen)
C-reactive protein standard Uric acid 
Hematology (approximately 3mL sample)
Complete blood count (red blood cells,
white blood cells, platelets, hemoglobin)White blood cell differential
Hematocrit
Urinalysis
pH Ketones 
Specific gravit y Bilirubin
Protein Blood 
Glucose
Shire CONFIDENTIAL Page 66
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis.  The microscopic examination will consist of red blood cells, white blood cells, casts,
and bacteria.
Please see Table 1, Table 2,and Table 3for visits requiring biochemistry , hematology  and 
urinaly sis collection.
7.2.2.7 Pregnancy Test 
A serum -HCG pregnancy test is performed for all females of childbearing potential at the 
following visits as applicable to the subject’s participation in the study : 
 Screening Visit (Visit 1)
 Double- blind Acute Phase: Week 8 (Visit 3.2)
 Open -label Acute Phase: Week 8 (Visit 4.2)
 Double- blind Maintenance Phase: Week 26 (Visit 5.2)
 If pregnancy  is suspected
 On withdrawal of the subject from the study .
A urine pregnancy  test is performed for all females of childbearing potential at 
all other visits as 
indicated in Table 1, Table 2 , and Table 3.
7.2.2.8 Stool Assessment
Collection of stool samples for all assessments must oc cur before administration of an y bowel 
preparations for endoscopy  if samples are collected on the same day  as bowel preparation 
administration.
If a standard of care stool sample has been collected within 24 hours prior to the Screening Visit 
(Visit 1), this sample may be used for screening assessments and evaluations provided that 
written informed consent/assent has been collected before the stool is sent for laboratory  
analysis.
Screening Assessments
A stool sample will be collected during the Screening Visit (Visit 1) ,which is a period of 
3to21days. If a standard of care stool sample was collected within 24 hours prior to the 
Screening Visit (Visit1) , this sample may  be used for screening assessments and evaluations. 
The sample must be collected in sufficient time to ensure results reporting within the Screening 
Visit (Visit 1) period Stool samples collected for culture may  be processed by  local laboratories;  
however, results from the central laboratory  anal ysis will prevail and will be entered into the 
eCRF . The following parameters will be assessed:
 Culture for enteric pathogens including Salmonella , Shigella , Yersinia , Aeromonas , 
Plesiomonas , and Campylobacter
Shire CONFIDENTIAL Page 70
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
PUCAI
The PUCAI is a ph ysician -administered measure that focuses on 6 key  signs and sy mptoms of 
UC and activity  limitations ( Turner et al. 2007 ).  The PUCAI y ields a total score ranging from 
0-85 with higher scores being worse.  Recommended cut -off scores to differentiate disease 
activity  are <10 (remission); 11
-30 (mild); 31- 64 (moderate) and >65 (severe) ( Turner et al. 
2009).  Evaluation of the construct validity  of the PUCAI  revealed that it was highl y correlated 
with phy sician’s global assessment of disease activity  and PUCAI scores were highl y predictive 
of the need for escala ting medical therapy  (Turner et al. 2009 ).  See 
Appendix 4 .
Only  sites who have executed a sublicense with Shire for PUCAI use will be able to collect 
PUCAI  data for the study.
IMPACT III
The IMPACT questionnaire is a disease -specific health -related quality-of-life questionnaire 
developed for use in pediatric inflammatory  bowel disease through a process of patient 
interviews and anal ysis of patient responses to an item-reduction questionnaire.  This is a 
self-administered questionnaire, and data will be collected via paper in this study .
The IMPACT questionnaire has been studied to determine its feasibility , reliability , and validity .  
It was found to be a valid and reliable refle ction of health -
related quality-of- life of older children 
and adolescents with both UC and Crohn's disease ( Otley  et al. 2002 ). 
In this stud y, the IMPACT III will be used.  This is the current version of the questionnaire, 
adapted from IMPACT II, which was developed in 2002.  The original version of I MPACT was 
developed in 1999.  IM PACT III contains 35 items in 6 domains.  The Bowel Sy mptoms domain 
and the 4 matching s ymptom items between the IMPACT III and the DUCS will be used to 
evaluat e convergent validity  of the DUCS.  
The IMPACT is valid for children and adolescents aged 9- 17 years old and is completed by  the 
subject.  Children/adolescent aged 9 -17 years who cannot complete the questionnaire 
independentl y, ma y be assisted by an adult who is not the child’s guardian or relative.  Children 
who are 8 years old may  complete the IMPACT with assistance from an adult who is not the 
child’s guardian or relative.  Children under the age of 8 y ears old will not complete the 
IMPACT.  
Global Change in Health
The Global Change in Health item assesses the subject’s (aged 11 -17 years) or caregiver’s (for 
children aged 5 -10 years) perception of change in health since starting the study  and will be 
administered via paper in this study .  This item has been tested in cognitive debriefing interviews 
with the DUCS.  
Shire CONFIDENTIAL Page 71
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
7.2.5 Volume of Blood to be Drawn from Each Subject
Table 6: Volume of Blood to be Drawn From Each Subject
Assessment Sample 
Volume 
(mL)Number 
of 
Samples: 
ScreeningNumber of 
Samples: 
Double -blind 
Acute PhaseNumber of 
Samples: 
Open -label 
Acute 
PhaseNumber of 
Samples: 
Double -blind 
Maintenance 
PhaseTotal 
Volume 
(mL)
Safety Biochemistry 
and -HCGa5 1 1 1 1 20
Hem atology 3 1 1 1 1 12
Pharm acokinetic samples 
(at particip ating sites only)2 0 1 1 1 6
Total mL 8 8 8 8 32-38
a -HCG testing for females only.
-HCG=beta -human chorionic gonadotropin
It is expected that approximately  32mL of blood will be drawn from subjects who participate in 
every  phase of the study , regardless of sex and approximately  an additional 6mL  will be drawn 
from subjects participating in the pharmacokinetic section of the study .  Blood sampling and 
volume drawn will be less for subjects who do not participate in every  phase of the study , in 
accordance with Table 6.
Note: The amount of blood to be drawn for each assessment is an estimate.  The amount of blood 
to be drawn may  vary  according to the instructions provided by  the manufacturer or laboratory  
for an individual assessment; however, the tot al volume drawn over the course of the study  
should be approximately  32-38mL .  When more than 1 blood assessment is to be done at the 
time point/period, if they require the same t ype of tube, the assessments may be combined.  
8. ADVERSE AND SERIOUS ADVERSE E VENTS ASSESSMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AEis an y untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatment.  An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not relat ed to the medicinal (investigational) product 
(International Council for Harmonisation [ ICH]Guidance E2A 1995).  
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.5 .  This includes events occurring during the screening phase of the 
study , regardless of whether or not investigational product is administered.  Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded.  If a diagnosis has not been made, 
then each s ymptom should be listed individually .  All AEs should be captured on the appropriate 
AE pages in the eCRF and in source documents.  In addition to untoward AEs, unexpected 
benefits outside the investigational product indi cation should also be captured i n the AE eCRF.
Shire CONFIDENTIAL Page 72
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
All AEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study .  Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained.  When appropriate, medical tests and examinations are performed so that resolution of 
event(s) c an be documented.
8.1.1 Severity Categorization
The severit y of AEs must be recorded during the course of the event including the start and stop 
dates for each change in severit
y.  An event that changes in severity should be captured as a new 
event.  Worsening o f pre-treatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more freque nt after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropri ate date of onset] is recorded i n the appropriate eCRF).
The medical assessment of severit y is determined by using the following definition s:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention.  The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specif ic therapeutic intervention.  The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE.  The investigator should deci de whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product.  If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”.   Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”.  The causalit y assessment must be 
documented in the source document.
Shire CONFIDENTIAL Page 73
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship betw een the event and the administration of the 
investigational product is compelling and/or follow s a known or suspected response 
pattern to that product, and the event cannot be explained by the subject’s medical 
condition, other therapies, or accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s underlying 
medical condition, concom itant therapy, or accident and no plausible temporal or 
biologic relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of th e stud y in the eCRF.  Outcomes are 
as follows:
 Fatal
 Not Recovered/Not Resolved
 Recovered/Resolved
 Recovered/Resolved With Sequelae
 Recovering/Resolving
 Unknown
8.1.4 Symptoms of the Disease Under Study
Symptoms of the disease under study  (eg, episodes of diarr hea with blood and mucus, abdominal 
pain, and urgency ) should not be classed as AEs as long as they  are within the normal day -to-day 
fluctuation or expected progression of the disease and are part of the efficacy  data to be collected 
in the study ; however, significant worsening of the sy mptoms should be recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory , or vital sign, assessment can represent an AE if the 
change is clinicall y relevant or if, d uring treatment with the investigational product, a shift of a 
parameter is observed from a normal value to an abnormal value, or a further worsening of an 
alread y abnormal value.  When evaluating such changes, the extent of deviation from the 
reference ra nge, the duration until return to the reference range, either while continuing treatment 
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into c onsideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory , or vital sign, values 
which were not present at the pretreatment value observed closest to the start of study  treatment, 
further investigations should be performed until the values return to within the reference range or 
until a plausible explanation (eg, concomitant disease) is found for the abnormal values.
Shire CONFIDENTIAL Page 74
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory , or vital sign, parameter is clinically  significant 
and therefore represents an AE.
Subjects with liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma -
glutam yl transferase ) elevated bey ond twice the upper limit of normal will be further evaluated 
with a panel of tests assessing markers of hepatic injury , inflammation, and function.  At a 
minimum, this panel should include the following: repeat alanine aminotransferase, aspartate 
aminotransferase, gamm a-glutamyl transferase , total and direct bilirubin, serum albumin, lactate 
dehy drogenase, and prothrombin time.  Consideration should be given as to whether an arterial 
blood sample for serum ammonia should also be obtained based on the magnitude of 
transa minase elevation and the subject’s clinical status (such as presence of mental status 
changes or other findings that might suggest Rey e’s syndrome; the Shire Medical Monitor 
should be consulted prior to collection of this specimen).  Subjects should be fol lowed until their 
hepatic enz yme values return to normal ranges.  If abnormal values persist for greater than 1 
week, the Shire Medical Monitor should be contacted for discussion and agreement of additional 
etiology  investigation. 
8.1.6 Pregnancy
All pregnancie s are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.5.
Any report of pregnancy  for any  female study  participant must be reported within 24 hours to the 
Shire Pharmacovigilance Department us ing the Shire Investigational and Marketed Products 
Pregnancy  Report Form.  The pregnant female study  participant must be withdrawn from the 
study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infan t.  It is the responsibility  of the investigator to obtain this information 
within 30 calendar day s after the initial notification and approximately  30 calendar day s 
post-partum. 
Pregnancy  complications such as spontaneous abortion/miscarriage or congenit
al abnormality  
are considered SAEs and must be reported using the Shire Clinical Trial Serious Adverse Event 
Form.  Note:  An elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets seri ous criteria, 
it must be reported as an SAE using the Shire Clinical Trial Serious Adverse Event Form as well 
as the Shire Investigational and Marketed Products Pregnancy  Report Form.  The test date of the 
first positive serum/urine -HCG test or ultrasoun d result will determine the pregnancy  onset 
date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2.  Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
Shire CONFIDENTIAL Page 75
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
The categories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse – Persistent or sporadic intentional intake of investigational product when used for a 
non-medical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individ ual and/or society
 Misuse – Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  the protocol)
 Overdo
se – Intentional or unintentional intake of a dose of an investigational product 
exceeding a pre -specified total daily  dose of 4.8g of the product
 Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product.  For studies, medication errors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The administration and/or use of an expired investigational product should be considered as a 
reportable medica tion error.
All investigational product provided to pediatric subjects should be supervised by  the 
parent/LAR/caregiver.
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the current MMX Me salazine (Mesalamine) 
Investigator’s Brochure which the sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire 
Pharmacovigilance Departmen t and the CRO Pharmacovigilance Department within 24 hours of 
the first awareness of the event.  Note: The 24 -hour reporting requirement for SAEs does not 
apply  to reports of abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they  
result in an SAE. 
The investigator must complete, sign, and date the Shire Clinical Trial Serious Adverse Event 
Form and verify  the accuracy  of the information recorded on the form with the corresponding 
source documents (Note:  Source documents are not to b
e sent unless requested) and fax or 
e-mail the form to the Shire Pharmacovigilance Department.  
Shire CONFIDENTIAL Page 76
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Acopy oftheShire Clinical Trial Serious Adverse Event Form (and an y applicable follow -up 
reports) must also be sent to the CRO Pharmacovigilance Department u sing the details specified 
in the emergency  contact information section of the protocol.
8.2.3 Serious Adverse Event Definition
AnSAE is any  untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose:
 Results in death.
 Is life -threatening.  Note: The term “life-threatening ”in the definition of “serious” refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
 Requires inpatient hospitalization or prolongation of existing hospitalization.  Note: 
Hospitalizations, which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened afte r initiation of treatment, should not 
be classified as SAEs.  For example, an admission for a previously  scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previou sly scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
 Results in persistent or significant disability /incapacity .
 Is a congenital abnormality /birth defect.
 Is an important medical event.  Note: I mportant medical events that may  not result in
death, be life -threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition.  Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions that 
do not result in inpatient hospitalization; or the development of drug de pendency  or drug 
abuse.  
8.2.4 Serious Adverse Event Collection Timeframe
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.5, and must be r eported 
to the Shire Pharmacovigilance Department within 24 hours of the first awareness of the event. 
In addition, any
 SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y interval after the study has completed must be reported to the Shire 
Pharmacovigilance Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria.  The re solution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic.  I n the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution da tes, respectivel y.
Shire CONFIDENTIAL Page 77
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date.  
For all other events ongoing at the time of death t hat did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAEs that result in the subject’s death or any ongoing events at the time of death, the 
action taken with the investig ational product should be recorded as “dose not changed” or “not 
applicable” (if the subject never received investigational product).
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and the clinical CRO are r esponsible for notify ing the relevant regulatory  
authorities/US central institutional review boards ( IRBs)/European U nion (EU) central ethics 
committees ( ECs) of related, unexpected SAEs.
In addition the clinical CRO is responsible for notify ing active sit es of all related, unexpected 
SAEs occurring during all interventional studies across the SPD476 program.  
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or h er site as required.
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the inform ation required by  the protocol 
in the e CRF.  A study  monitor will visit each site in accordance with the monitori ng plan and 
review the eCRF data against the source data for completeness and accuracy .  Discrepancies 
betwee n source data and data entered i n the e CRF will be addressed b y qualified site personnel.  
When a data discrepancy warrants correction, the correct ion will be made by  authorized site 
personnel.  Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting.  Once a subject is randomized, it is expected that site 
personnel will complete the eCRF entry  within approximately  3 business day s of the subject’s 
visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan.  
Quality  control and data validation procedures are applied t o ensure the validity  and accuracy  of 
the clinical database.
Shire CONFIDENTIAL Page 78
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures.  Data queries requiring clarification are 
to be com municated to the site for resolution.  Only authorized personnel will make corrections 
to the clinical database, and all corrections are documented in an auditable manner.
9.3 Data Handling Considerations
Data that may  potentiall y unblind the treatment assignment (ie, investigational product serum 
concentrations, treatment allocation, and investigational product preparation/accountability  data) 
will be handled with special care during the data cleaning and review process.  These data will be 
handled in such a w ay that, prior to unblinding, any  data that may  unblind study  team personnel 
will be presented as blinded information or otherwise will not be made available.  If applicable, 
unblinded data may  be made available to quality  assurance representatives for the purposes of 
conducting independent drug audits. 
9.4 Statistical Analysis Process
The study  will be anal yzed by  the sponsor or its agent.   All data anal yses will be performed b y 
the Biometrics Department of the CRO after the study  is completed and unblinded, and the 
database is released for analy sis.
The statistical anal ysis plan ( SAP)will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other stud y information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.  The 
SAP will also include a description of how missing, unused, and spurious data will be addres sed.
The SAP will be finalized prior to unblinding to preserve the integrit y of the statistical anal ysis 
and study  conclusions.  
All statistical analy ses will be performed using SASVersion 8.2 (SAS I nstitute, Cary , NC 
27513) or later version. 
9.5 Planned I nterim Analysis, Adaptive Design, and Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will be established for this study .  The 
purpose of the DMC is to review safet y data (eg, AEs, clinical laboratory
 data) .  DMC meetings 
will be h eld when data is available from specified percentages of subjects who have completed 
or withdrawn from a phase or phases during the study .  The data provided to the DMC will not 
be considered “clean” until the database is locked. Data will be provided to t he DMC by  an 
independent statistical reporting group not assigned to the project. Further details regarding the 
DMC and meeting frequency  can be found in the DMC charter .  
Shire CONFIDENTIAL Page 79
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
9.6 Sample Size Calculation and Power Considerations
This will be an estimation study  with no formal hy pothesis testing; therefore, this study is not 
powered to detect differences between treatment groups. More than 100 subjects will be screened 
and up to 80 subjects will be enrolled in the Double -blind Acute Phase of the study . More than 
65 subjects will be screened (in addition to an expected 28 subjects who will enter the 
Double-blind Maintenance Phase from one of the Acute Phases) and at least 80subjects will be 
enrolled in the Double -blind Maintenance Phase of the study . The sample size waschosen based 
on practical considerations and on agreement with the US FDA.
9.7 Study Population
The Screened Set will consist of all subjects who have signed an informed consent.
The Double -blind Acute Phase Safety Analysis Set will consist of randomized subjects who 
have taken at least 1 dose of investigational product during the Double -blind Acute Phase.
The Open -label Acute Phase Safety Analysis Set will consist of all subjects who have taken at 
least 1 dose of investigational product during the Open
-label Acute Phase.
The Double -blind Maintenance Phase Safety Analysis Set will consist of randomized subjects 
who have taken at least 1 dose of investigational product during the Double -blind Maintenance 
Phase.
9.8 Efficacy Analyses
Baseline is defined as the last observation prior to first dose of investigational product in the 
study .  The Double -blind Acute Phase Week 8/Withdrawal visit (Visit 3.2) is treated as the 
Open -label Acute Phase Week 0 for subjects continuing into the Open- label Acute Phase from 
this visit. The Double -blind Acute Phase Week 8/Withdrawal visit (Visit 3.2) is treated as the 
Double-blind Maintenance Phase Week 0 for subjects continuing into the Double- blind 
Maintenance Phase from this visit. The Open- label Acute Phase Week 8/Withdrawal vi sit (Visit 
4.2) is treated as the Double -blind Maintenance Phase Week 0 for subjects continuing into the 
Double- blind Maintenance Phase from this visit. For subjects who enter the Double -blind 
Maintenance Phase directly , the Baseline Visit (Visit 2) is tr eated as the Double -blind 
Maintenance Phase Week 0.
9.8.1 Primary Efficacy Endpoint
The primary endpoints for this study  are defined separately  for both the Double -blind Acute 
Phase and Double -blind Maintenance Phases and will be conducted using the appropriate Sa fety 
Analy sis Set for the Phase.
9.8.1.1 Double -blind Acute Phase 
The primary  efficacy  endpoint for the Double -blind Acute Phase is defined as the proportion of 
subjects with a clinical response (defined as partial UC -DAI≤1 with rectal bleeding=0 andstool 
frequency  ≤1 andPGA=0) at Week 8.
Shire CONFIDENTIAL Page 80
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Subjects with missing data at Week 8 will be assumed not to have had a clinical response.  The 
primary  efficacy  endpoint will be compared between treatment arms using a continuity -corrected 
chi-squared test on the Double -blind Acute Phase Safety  Anal ysis Set.  The null hy pothesis to be 
tested is that there is no difference in the proportion of subjects with a clinical response at Week 
8 between low and high doses of MMX mesalamine/mesalazine.
9.8.1.2 Double -blind Maintenance Phase 
The primary  efficacy  endpoint for the Double -blind Maintenance Phase is defined as the 
proportion of subjects who have maintained a clinical response (defined as partial UC -DAI≤1 
with rectal bleeding=0 andstool frequency  ≤1 andPGA=0) at Week 26.
Subjects with missing data at Week 26 will be assumed not to have had a clinical response.  The 
primary  efficacy  endpoint will be compared between treatment arms using a Cochran -Mantel-
Haenszel (CMH )test stratify ing for 3 lev els of responder status at Week 26 of the Double -blind 
Maintenance Phase (entered Maintenance Phase directly , responder at Week 8 of the Double -
blind Acute Phase, or responder at Week 8 of the Open- label Acute Phase) on the Double -blind 
Maintenance Phase Safety Analy sis Set.  The null hy pothesis to be tested is that there is no 
difference in the proportion of subjects with a clinical response at Week 26 between low and 
high doses of MMX mesalamine/mesalazine .
9.8.2 Sensitivity Analyses of the Primary Endpoint
The following sensitivity anal yses will be performed for both the Double- blind Acute and 
Double- blind Maintenance Phase primary  endpoints:
A modified clinical response, defined as partial UC- DAI≤1 with rectal blee ding=0 and stool 
frequency  ≤1 will be analy zed in a similar way  to the primary  endpoint analy sis in order to 
investigate the effect of removing the PGA component from the responder definition.
An observed -case anal ysis will be performed, where data from th
ose who completed Week 
26 and those who withdrew from the stud y earl y and are presented and analyzed separatel y, 
using a similar analy sis to the primary  endpoint.  
A complete -case anal ysis, where subjects who withdraw earl y from the study will be 
excluded, will be performed in a similar way  to the primary  endpoint analy sis.
A last observation carried forward anal ysis, using data from the final on- treatment 
assessment, will be performed in a similar way  to the primary endpoint analy sis.
Logistic modeling wi ll be conducted to investigate the effect of doses in mg/kg on the 
clinical response in the Double- blind Acute and Double -blind Maintenance Phases.  
9.8.3 Secondary Efficacy Endpoints
The secondary endpoints for this study  are defined separately for both the Double -blind Acute 
and Double -blind Maintenance Phases and will be conducted using the appropriate Safety  
Analy sis Set for the Phase.  These endpoints will be described using appropriate summary  
statistics (n [%]) for categorical variables, n, mean, standard deviation, median, minimum and 
maximum for continuous variables).
Shire CONFIDENTIAL Page 83
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
9.10 Other Analyses
9.10.1 Health -related Quality -of-Life Analyses
In this stud y the final validation steps for the PRO instrument, the DUCS, will be perf ormed.  
The psy chometric properties of the DUCS, including reliability , validity , and responsiveness, 
will be examined using data from an appropriate number of subjects from the Double -blind 
Acute Phase and an appropriate number of subjects from the Double -blind Maintenance Phase 
prior to unblinding.  To examine convergent validity , the DUCS scores will be correlated with 
the IMPACT III, Overall Current Health and selected clinical data. 
The validation of the DUCS will be described in a separate SAP specif ic for the DUCS.
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements.  
The name and address of each third part y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice ( GCP )Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accor dance with current GCP and the respective local and 
(inter)national government regulations and guidelines.  Records and data may  additionally  be 
reviewed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority requirem ents are met before the start of the 
study .  The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for sh ipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines.   If appropriate, a cop y of the indemnity document is 
supplied to the investi gator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study .  An insurance certificate is supplied to the CRO/investigator as necessary .
Shire CONFIDENTIAL Page 84
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites.  
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regul atory  requirement(s) and to comply  with the 
Community  guideline on GCP.  This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance.  The spon sor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason.  
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory  
agencies, and IRBs/ECs are notified as appropriate.  Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an end -of-study  declaration to the relevant competent authority  as 
required b y Article 10 (c) of Directive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in acc ordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site pri or to commitment to participate in this study .  The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -
related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification.  Curriculum vitae for investigators and sub -investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
Shire CONFIDENTIAL Page 85
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
A coordinating principal investigator is appointed to review the final clinical study  report for 
multicenter studies.  Agreement with the final clinical study  report is documented by  the signed 
and dated sign ature of the coordinating principal investigator, in compliance with Directive 
2001/83/EC as amended by  Directive 2003/63/EC and I CH Guidance E3 ( 1995 ). 
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y co-
investigators must adhere to the protocol as detailed in this 
document.  The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria.  Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness t o comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation.  The 
investigator will also return all investigational product, containers, and other study  materials to 
the sponsor.  Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local IRBs/ECs, to ensure that accurate and timely  information is provided 
at all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator acc ording to national provisions and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Electronic Case Report Forms
Electronic c ase report forms are supplied by the CRO and should be handled in accordance with 
instructio ns from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which acc urate information is recorded in to eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation.  Electronic case report forms 
must be completed by  the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
All data sent to the spo nsor must be endorsed b y the investigator.
The clinical research associate/study  monitor will verify  the contents against the source data per 
the monitoring plan.  If the data are unclear or contradictory, queries are sent for corrections or 
verification o f data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file including histology  reports, subject -completed questionnaires and original 
clinical laboratory  reports.
Shire CONFIDENTIAL Page 86
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The clinical research associate/study  monitor (and auditors, I RB/EC or regulatory  inspectors) 
may check the eCRF entries agai nst the source documents.  The consent/assent form includes a 
statement by  which the subject/L AR agrees to the monitor/auditor from the sponsor or its 
representatives, national or local regulatory  authorities, or the I RB/EC, having access to source 
data (e g, subject’s medical file, appointment books, original laboratory  reports, X -rays etc).  
Non-study  site personnel will not disclose any  personal information or personal medical 
information.
These records must be made available within reasonable times for i nspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency , United Kingdom Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon reque st by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the European Medicines Agency , the United Kingdom 
Medicines and Healthcare products Regulatory  Agency , other regulatory  authorities, the spon sor 
or its representatives, and the I RB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  the value of th e compensation for 
conducting the study , or other pay ments the investigator received from the sponsor.  The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  interest in the sponsor or subsidiaries as defined in Title 21of the US Code of 
Federal Regulations Part54 2(b) (1998).
10.3 Ethical Considerations
10.3.1 Informed Consent/Assent
It is the responsibility  of the investigator to obtain written informed consent and assent 
where applicable from all study  subjects prior to any  study -related procedures including 
screening as sessments.  
Shire CONFIDENTIAL Page 87
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
Allconsent andassent documentation must beinaccordance with applicable regulations and 
GCP.  Each subject or the subject’s LAR, as applicable, is requested to sign and date the subject 
informed consent/assent form or a certified translation if applicable, after the subject has 
received and read (or been read) the written subject information and received an explanation of 
what the study  involves, including but not limited to: the objectives, potential benefits and risk, 
inconveniences, and th e subject’s rights and responsibilities.  A copy  of the informed consent 
and assent documentation (ie, a complete set of subject information sheets and fully  executed 
signature pages) must be given to the subject or the subject’s LAR, as applicable.  This document 
may require translation into the local language.  Signed consent/assent forms must remain in 
each subject’s study  file and must be available for verification at any time.
Within the source documents, site personnel should document instruction of a nd understanding 
by the parent/LAR/caregiver of the safe, responsible storage and administration of 
investigational product to the study  subject.
The principal investigator provides the sponsor with a cop y of the consent form and assent form 
where applicab le which was reviewed by  the IRB/EC and which received their favorable 
opinion/approval.  A copy  of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  regulatory  guidelines and national provisions) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action.  Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent/assent document (approved b y the sponsor or their designee), relevant 
supporting information and all ty pes of subject recruitment information to the I RB/EC for 
review, and all must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility  for coordi nating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent/assent documents and amendments to the protocol unless there 
is a subje ct safet y issue.
Investigational product supplies will not be released until the sponsor has received written 
IRB/EC approval of and copies of revised documents.
Shire CONFIDENTIAL Page 89
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information.  The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study .  To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with other authors) the 
copy right on his/her publications.  To the extent that the principal investigator has such sole, 
joint or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free l icense to make and distribute copies of such publications.
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts, and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, t he investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other scholars to verify such stud y 
results.  Notwi thstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days pri or to 
submission for publication.  If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a patent application.
If the stud y is part of a multicenter study , the first publication of the study  results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results.  If such a multicenter publication is not submitted to 
a journal for publication by the sponsor within an 18 -month period after conclusion, 
abandonment, or termination of the study  at all sites, or after the sponsor confirms there shall be 
no multicenter study  publication of the study  results, an investigator may  individually  publish the 
study  results from the specific site in accordance with this section.  The investigator must, 
however, acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwi se required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards.  Participation as an investigator does not confer an y right s to authorship of 
publications.
Shire CONFIDENTIAL Page 90
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
11. REFERENCES
Mendeloff AI, Calkins BM 1988.  The epidemiology  of idiopathic inflammatory  bowel disease.  
In: Kirsner, JB, Shorter, RG (Eds), Inflammatory Bowel Disease .  Lea Febiger, Philadelphia.  
Otley  A, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, et al. 2002.  The IMPACT 
Questionnaire: A valid measure of health -related quality  of life in pediatric inflammatory  bowel 
disease.  J Pediatr Gastroenterol Nutr ; 35(4): 557 -63.
Turner D, Otley  A, Mack D, Hyams J, De Bruijn e J, Uusoue K, et al. 2007.  Development, 
validation, and evaluation of a pediatric ulcerative colitis activity  index: a prospective 
multicenter study .  Gastroenterology ; 133: 423 -32.
Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, et al. 2009. Appraisal of the 
Pediatric Ulcerative Colitis Activity  Index (PUCAI).  Inflamm Bowel Dis ; 15(8): 1218 - 23.
Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. 2012.  Management 
of pediatric ulcerative colitis: Joint ECCO and ESPGHAN evidence -based consensus guidelines.  
J Pediatr Gastroenterol Nutr ; 55(3): 340 -61.
Schroeder KW, Tremaine WJ, Ilstrup DM 1987.  Coated oral 5-aminosalicy lic acid therap y for 
mildly  to 
moderatel y active ulcerative colitis.  A randomized study .  N Engl J Med; 317(26): 
1625-9.
Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 1987.  
5-Aminosalicy lic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and 
proctitis.  
Gastroenterology ; 92(6): 1894 -8.
Shire CONFIDENTIAL Page 91
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
12. APPENDICE S
Shire CONFIDENTIAL Page 100
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
APPENDIX 2 THE MODIFIED FULL UL CERATIVE CO LITIS DISEASE 
ACTIVITY INDEX (UC -DAI)
The modified full UC -DAI Score is computed as the sum of scores in 4 categories of clinical 
symptoms: stool frequency , rectal bleeding, and mucosal appearance (endoscopy  score) and 
PGA.
The 4 components of the modified full UC -DAI are scored in the following way :
Stool frequency  Score
Normal 0
1-2 more than normal/day 1
3-4 more than normal/day 2
>4 more than normal/day 3
Rectal bleeding (most severe bleeding of the day )
None 0
Streaks of blood 1
Obvious blood 2
Mostly  blood 3
Mucosal appearance (endoscopy  score)
Normal (intact vascular pattern; no friability  or granulation) 0
Mild (erythema, decreased vascular pattern, minimal 
granularit y)1
Moderate (marked erythema, granularit y, friability , absent 
vascular pattern, bleeding with minimal trauma, no ulcerations)2
Severe (ulceration, spontaneous bleeding) 3
Physician’s Global Assessment
No active disease 0
Mild disease 1
Moderate disease 2
Severe disease 3
Shire CONFIDENTIAL Page 101
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
APPENDIX 3 SUBJECT QUESTIONNAIR ES
The following subject completed questionnaires will be utilized in this study :
Daily  Ulcerative Colitis Scale for Children and Caregivers
Overall Current Health
Rectal Bleeding
Stool Frequency
Global Change in Health
IMPACT III
A separate master file containing each subject qu estionnaire listed above will be provided to the 
site.  Updates to subject questionnaires during the study  (if applicable) will be documented in the 
table above and a new master file containing the revised subject questionnaire(s) will be 
provided to the site.
Shire CONFIDENTIAL Page 102
SPD476 -319 Protocol Am endm ent 5
SPD476 10 Apr 2017
APPENDIX 4 PEDIATRIC ULCERATIVE COLITIS ACTIVITY I NDEX
